Genotype-Phenotype Correlations Among Two Large Western Pennsylvania Von Hippel-Lindau Disease (VHL) Type 2A Kindreds with High Incidence of Pheochromocytoma and Different Missense Mutations in the VHL Gene by Nielsen, Sarah Marie
 GENOTYPE-PHENOTYPE CORRELATIONS AMONG TWO LARGE WESTERN 
PENNSYLVANIA VON HIPPEL-LINDAU DISEASE (VHL) TYPE 2A KINDREDS 
WITH HIGH INCIDENCE OF PHEOCHROMOCYTOMA AND DIFFERENT 
MISSENSE MUTATIONS IN THE VHL GENE 
 
 
 
 
 
 
 
 
by 
Sarah Marie Nielsen 
BA, Lehigh University, 2008 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
the Graduate School of Public Health in partial fulfillment  
of the requirements for the degree of 
Master of Science 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
2010 
 
 ii 
UNIVERSITY OF PITTSBURGH 
GRADUATE SCHOOL OF PUBLIC HEALTH 
 
 
 
This thesis was presented 
 
by 
 
 
Sarah Marie Nielsen 
 
 
 
It was defended on 
April 16, 2010 
and approved by 
 
 
Thesis Advisor: Sally E. Carty MD, Professor of Surgery,  
Chief, Section of Endocrine Surgery 
School of Medicine, University of Pittsburgh  
 
Eleanor Feingold PhD, Professor, Department of Human Genetics  
Graduate School of Public Health, University of Pittsburgh  
 
Robert E. Ferrell PhD, Professor, Department of Human Genetics 
Graduate School of Public Health, University of Pittsburgh  
 
Darcy L. Thull MS, CGC, Cancer Genetics Counselor 
Cancer Genetics Program, University of Pittsburgh Cancer Institute 
 
 
 
 iii 
Copyright © by Sarah M. Nielsen 
2010 
 iv 
  
Von Hippel-Lindau disease (VHL) type 2A is a rare inherited tumor predisposition syndrome, 
which is primarily associated with benign tumors of the blood vessels of the central nervous 
system and eyes and benign tumors of the adrenal gland, though renal cell carcinoma (RCC) can 
also be part of this tumor spectrum. Two large regional VHL type 2A kindreds have been 
assessed over decades at the University of Pittsburgh.  Both kindreds have markedly high rates of 
adrenal and extra-adrenal pheochromocytoma, and almost no cases of RCC.  By mutational 
analysis, each kindred has a separate disease-causing missense mutation of the VHL gene: 
Y112H (334 T to C) in Family 1, and Y98H (292 T to C) in Family 2.  Both gene changes arise 
from a tyrosine to histidine substitution in exon 1 of the VHL gene on chromosome 3p25.  
Phenotypic expression in the family with Y112H (Family 1) has been described in the past, 
however the phenotype related to Y98H (Family 2) has not heretofore been described.  Although 
these mutations are similar and occur within the same region of the gene, I hypothesize that there 
are differences in disease expression between the families, particularly related to 
pheochromocytoma. The aim of this study is to evaluate the phenotypic expression of VHL in 
these genotypically different VHL type 2A kindreds.   
Public Health Significance:
GENOTYPE-PHENOTYPE CORRELATIONS AMONG TWO LARGE WESTERN 
PENNSYLVANIA VON HIPPEL-LINDAU (VHL) TYPE 2A KINDREDS WITH HIGH 
INCIDENCE OF PHEOCHROMOCYTOMA AND DIFFERENT MISSENSE 
MUTATIONS OF THE VHL GENE 
 Although VHL disease is clinically rare, the treasure trove of 
information provided by large VHL type 2A kindreds can help to clarify phenotype, penetrance, 
and survival patterns as well as further define surveillance algorithms.   
 
 Sarah Marie Nielsen, M.S. 
University of Pittsburgh, 2010 
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1.0  INTRODUCTION 
Von Hippel-Lindau disease (VHL) is an autosomal dominant endocrine tumor syndrome 
characterized by benign and malignant tumors of various organ systems including the brain, 
eyes, spine, adrenal glands, para-aortic sympathetic chain, pancreas and kidney.  The U.S. 
incidence of VHL is approximately 1 in 32,000 persons [VHL Family Alliance].   Clinical 
heterogeneity is a hallmark of VHL, and four phenotypes have been described based on the 
relative incidences of pheochromocytoma and renal cell carcinoma (RCC) (Table 1) [Chen et al, 
1995; Neumann and Wiestler, 1991; Zbar et al 1996].   
Pheochromocytomas are rare tumors of neural crest origin that secrete one or several 
catecholamines (epinephrine [adrenaline], norepinephrine, and/or dopamine), which are the 
hormones of the sympathetic fight-or-flight response.  Pheochromocytomas have variable 
malignant potential (5-30%). The prevalence of pheochromocytoma in Western countries is 
between 1 in 6,500 to 1 in 2,500, with an annual incidence in the U.S. of 500 to 1,100 cases 
[Pacak et al., 2002]. Signs or symptoms include intermittent or sustained hypertension and/or 
“spells” of palpitations, tachycardia, headaches, episodic sweating, pallor and nausea [Lonser et 
al, 2003], but as many as a third of pheochromocytomas are asymptomatic at presentation.  If left 
untreated, pheochromocytoma is fatal, primarily due to complications of hypertension that 
include heart attack, heart failure, stroke, kidney failure and cognitive decline [Tisherman et al, 
1993].  Pheochromocytoma is a unique tumor type in that its manifestations and risks are not the 
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classic complications of solid tumor mass, local spread, and distant metastasis, but are much 
more often the complications of its’ hormonal secretion.     
VHL type 1 carries a low risk of pheochromocytoma (<5%), while VHL type 2 is 
characterized by a high rate of pheochromocytoma (>60%) [Chen et al, 1995; Zbar et al, 1996].  
By 1995, approximately 77% of the families described had VHL type 1 [Chen et al, 1995].  VHL 
type 2 is subdivided into three categories: type 2A is characterized by pheochromocytoma, 
retinal angioma and hemangioblastoma, but rarely RCC; type 2B carries a high rate of RCC (up 
to 70%) plus pheochromocytoma, hemangioblastoma and pancreatic cysts; and type 2C carries 
the risk of pheochromocytoma alone [Woodward et al., 1997; Zbar et al., 1996].    
Pheochromocytoma can also be sporadic, or can be a component of several other genetic 
conditions such as multiple endocrine neoplasia type 2A (MEN2A) (pheochromocytoma 
penetrance is ~50%), multiple endocrine neoplasia type 2B (MEN2B) (penetrance ~40%), or 
neurofibromatosis type 1 (NF1) (penetrance 0.1%-5.7%) [Neumann et al., 1993].  Recently a 
new form of inherited pheochromocytoma has been reported in patients with nonsyndromic 
familial pheochromocytoma or paraganglioma.  These patients have been found to have germline 
mutations in the succinate dehydrogenase (SDH) genes, including SDHB, SDHC and SDHD. 
The majority (~97%) of mutations identified are in the SDHD gene, which is imprinted and 
associated with paraganglioma or pheochromocytoma susceptibility only after paternal 
transmission [Baysal et al., 2002, reviewed in Favier et al., 2005].   
Members of 2 VHL type 2A families have been followed for decades through the 
University of Pittsburgh.  Family 1 has over 1000 members, and has been described several 
times in the literature.  Branches of Family 2 have been assessed briefly in the literature as part 
of larger studies that sought to localize the VHL gene, establish genotype-phenotype correlations, 
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and/or provide evidence of a founder effect [Brauch et al., 1995, Chen et al., 1995; Glenn et al., 
1991, Hosoe et al., 1990], but Family 2 has never been described independently in the literature.  
The majority of both families’ members reside in Western Pennsylvania, giving us a unique 
opportunity to study them over the years.  Although both families have markedly high incidences 
of pheochromocytoma, and at least anecdotally may have no cases of RCC (see Results), these 2 
families have different VHL-causing mutations of the same region of the VHL gene, Y112H in 
Family 1 and Y98H in Family 2.  I hypothesized that the genetic differences of these families 
may correlate with differences in phenotypic expression, and to analyze this I systematically 
examined the clinical and pathologic characteristics of affected patients with documented 
pheochromocytoma.  
  
  
1.1 BACKGROUND OF STUDY 
1.1.1 Family 1 
Family 1 is a famous Pittsburgh-area regional VHL type 2A kindred that was described almost 
five decades ago to manifest a high rate of pheochromocytoma [Tisherman, Gregg, Danowski, 
1962].  This family was initially identified and laboriously tabulated by Dr. Samuel A. 
Tisherman, a prominent Pittsburgh internist who passed away in 2000.  His work began when, as 
a resident trainee, he identified a 21-year-old man hospitalized for severe hypertension; familial 
pheochromocytoma was suspected because the family history revealed 4 other family members 
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with that rare tumor.  In Dr. Tisherman’s initial report, 7 patients with confirmed 
pheochromocytoma and 1 patient with suspected pheochromocytoma were identified, and in 
follow-up, 8 additional relatives were diagnosed with pheochromocytoma.   
Working assiduously over decades, and prior to the mapping of the VHL gene defect, Dr. 
Tisherman traced the family’s roots back to early 16th century Germany to the town of Leipzig in 
the east-central state of Saxony (Figure 1).  It is believed that Family 1 arrived in America 
around 1670 and subsequently spread throughout the United States, with over half of the 1200 
descendents of the original 11 siblings settling in western Pennsylvania [Tisherman et al., 1993]. 
In 1993, in a 30-year phenotype characterization, Dr. Tisherman expanded the family tree to 
chart 7 generations with at least 1195 known relatives; over the years, and often by the means of 
summer picnics, he personally met with and/or partially evaluated at least 522 Family 1 
descendants [Tisherman et al., 1993].  By 1993, Family 1 had 19 known affected individuals, 16 
with pheochromocytoma, 4 with retinal angioma and one with CNS hemangioblastoma 
[Tisherman et al., 1993], for a rate of pheochromocytoma among those clinically affected of 
84.2%.  Ten additional individuals were determined to have VHL type 2A by virtue of being 
obligate carriers.  Family 1 remains the largest kindred with pheochromocytoma described in the 
literature to date.  The present research further updates and expands this pedigree, including 20 
newly described patients with VHL type 2A.   
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Figure 1. Map of Germany with Regions of Origin of VHL Type 2A Families.   
The Pfalz region is spotted and the Black Forest is hatched. The open circle indicates the area of 
origin of 14 Black Forest families. The filled circle indicates the place of origin of the founder 
member of the Family 2 prior to emigration.  The filled square indicates the place of origin of the 
ancestors of Family 1. The surrounding area marked by x’s represents the state of Saxony. 
Adapted from [Brauch et al., 1995].  
 
 
 
Dr. Tisherman’s work was influential in establishing routine clinical care for patients 
with VHL type 2A and in clarifying the genetics of the disease.  In studying multiple generations 
of the same family, he reported that compared to historical controls, education and surveillance 
could decrease mortality from pheochromocytoma [Tisherman et al., 1993].  The extensive DNA 
bank established by his work aided in its localization to chromosome 3p25-26 by linkage 
analysis [Hosoe et al., 1990] and in the isolation of the VHL gene by positional cloning [Latif et 
al., 1993].  Subsequently, a germline mutation at what was previously nucleotide 547 (now 
nucleotide 334) was identified in 31 Family 1 members with a diagnosis of pheochromocytoma, 
retinal angioma, or both [Mulvihill et al., 1997]. 
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1.1.2 Family 2   
Family 2 members with VHL type 2A have been evaluated at the University of Pittsburgh 
for about 2 decades.  The proband was a 9 year-old boy who was found to have multifocal and 
bilateral pheochromocytoma as part of a work up for hypertension, which is itself unusual in 
children.  Shortly after his pheochromocytoma surgery, his older brother was diagnosed with 
bilateral pheochromocytoma. Their sister was the first patient for Dr. Carty’s practice; at 33 she 
reported pheochromocytoma symptoms, slipped on ice and suffered a pathologic T8 fracture, and 
was discovered to have a paraspinal mass that was metastatic pheochromocytoma.  She also was 
found to have 13 siblings; of these, 12 carry the VHL gene and all 12 have since been diagnosed 
with pheochromocytoma.  Her father and other extended family members also came to attention 
after their children’s diagnoses.  
VHL type 2A in Family 2 is likely to have originated 4 generations back, but information 
is only available for 3 generations back to the proband’s paternal great-grandfather, who died at 
the age of 89 with heart failure after reported loss of sight in one eye at age 30.  Some members 
of the Family 2 have received genetic testing and evaluation through the National Institutes of 
Health (NIH), and a germline mutation in the VHL gene at what was previously nucleotide 505 
(now nucleotide 292) was identified [Brauch et al., 1995; Chen et al., 1995].   
1.2 GENETICS OF VHL  
VHL is an autosomal dominant disease that results from a germline mutation in the VHL gene 
located on chromosome 3p25-25 [Latif et al., 1993; Linehan, Lerman, Zbar, 1995].  The 
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resulting tumors can be benign or malignant, and present in endocrine glands as well as non-
endocrine organs.  Overall penetrance is over 90% by 65 years of age [Maher et al., 1991].  The 
initial manifestations can occur in childhood, adolescence or later, with an overall mean age of 
presentation of about 26 years [Maher et al., 1990].  Approximately 80% of individuals with 
VHL have an affected parent and about 20% have VHL as the result of a de novo gene mutation 
Although parental mosaicism has been described, the incidence is not known [Schimke, Collins, 
Stolle, 2000].   
The diagnosis of VHL is established in one of 3 ways.  First, in a patient with no family 
history of VHL, the condition is diagnosed by the presence of 2 or more CNS 
hemangioblastomas (including retinal angioma), or one CNS hemangioblastoma and a visceral 
tumor (pancreatic cysts or tumors, RCC, or pheochromocytoma).  However, epididymal and 
renal cysts are not considered in the diagnosis since they are frequent in the general population 
[Melmon and Rosen, 1964; Neumann, 1987; Hosoe et al., 1990].  Second, when there is a 
positive family history of VHL, the diagnosis is made in a first-degree relative with a CNS 
hemangioblastoma (including retinal angiomas), pheochromocytoma, or clear cell renal 
carcinoma (diagnosed before the age of 60) [Melmon and Rosen, 1964; Neumann, 1987; Hosoe 
et al., 1990].  Third, molecular genetic testing is now the gold standard for establishing a 
diagnosis of VHL since germline VHL mutations have been identified in virtually all VHL 
families.  As such, locus heterogeneity is not known to exist in VHL although allelic 
heterogeneity is a hallmark of the disease and is discussed further below.   
The VHL gene consists of 3 exons that encode the VHL protein, including 712 
nucleotides and 70 base pairs of 5’ untranslated sequence in exon 1 [Maher and Kaelin, 1997].  
Two mRNA isoforms differ based on the presence or absence of exon 2 [Gnarra et al., 1994].  
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The normal VHL gene product (pVHL) has many cellular roles including transcriptional 
regulation, post-transcriptional gene expression, protein folding, extracellular matrix formation, 
microtubule stability, and ubiquinylation (Hergovich et al., 2003; Kaelin, 2007; Roberts and 
Ohh, 2008].  Among the best characterized defects in cells with inactive pVHL is the inability to 
regulate the function of hypoxia-inducible factor (HIF) leading to increased activation of genes 
involved in angiogenesis and resulting in RCC and the other highly vascularized tumors [Kaelin, 
2002].  
VHL is a tumor suppressor gene. Thus tumorigenesis occurs in accordance with 
Knudson’s two-hit hypothesis requiring both VHL alleles to be inactivated for tumors to form 
[Knudson and Strong, 1972; Tory et al., 1989].  This is evidenced by examination of a variety of 
tumor types from patients with VHL that consistently show loss of the VHL wildtype allele, as 
well as the identification of somatic mutations of the VHL gene in patients with sporadic clear 
cell RCC and CNS hemangioblastomas [reviewed in Maher and Kaelin, 1997]. Over 500 
germline mutations have been identified in families with VHL [Beroud et al., 1998].  In a 
heterogenous group of type 1 and type 2 VHL patients, these mutations include partial and 
complete gene deletions (15%-20% of patients) as well as missense (27%), frameshift or 
nonsense (27%), and splice site mutations [Beroud et al., 1998; Crossey et al., 1994; Maher and 
Kaelin, 1997].  Later studies using improved diagnostic techniques have allowed detection of 
mutations in nearly 100% of patients with confirmed VHL [Stolle et al., 1998].  The majority of 
mutations are private with only a handful of mutations found in 4 or more families.  However, 
codon 167 appears to be a mutation “hot spot,” conveying a high risk for both 
pheochromocytoma and RCC in Japanese, French, UK, and American families alike [Beroud et 
al., 1998; Zbar et al., 1996].    
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1.2.1 Genotype-Phenotype Correlations in VHL  
Several VHL genotype-phenotype correlations have been described and are particularly useful in 
prognostic counseling regarding the risk of pheochromocytoma.  The clear correlation of 
genotype with phenotype has already allowed for classification of 4 clinical subtypes of VHL 
based on risk of pheochromocytoma (above), including type 1 (RCC, pancreatic neoplasms and 
cysts, CNS hemangioblastoma, retinal angioma), type 2A (pheochromocytoma, CNS 
hemangioblastoma, retinal angioma), type 2B (pheochromocytoma, CNS hemangioblastoma, 
retinal angioma, RCC), and type 2C (pheochromocytoma only).  In VHL type 1, about 60% of 
germline mutations in patients without pheochromocytoma are known to be 
microdeletions/insertions, nonsense mutations, or large deletions, whereas in VHL type 2 
patients with pheochromocytoma, 96% of germline mutations are known to be missense, with 
43% of these being at codon 238 [Chen et al., 1995] (Table 1).  
 
Table 1.  VHL Subtypes and Genotype-Phenotype Correlations  
VHL subtype VHL mutation HB RCC Pheo 
1 Deletion, Insertion, 
Nonsense, Missense 
High risk High risk Low risk 
2A Missense High risk Low risk High risk 
2B Missense High risk High risk High risk 
2C Missense Low risk Low risk High risk  
HB, hemangioblastoma; RCC, renal cell carcinoma; Pheo, pheochromocytoma  
Adapted from [Bryant et al. 2003] 
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Before the precise location of the VHL locus on chromosome 3 was identified, Family 2 
members were a part of a 1991 report from NIH, which first observed that different mutant 
alleles at the same VHL locus were associated with “distinct tissue specificities.”  Family 2 and 
several other smaller families were characterized by a high frequency of pheochromocytoma and 
a low frequency or absence of RCC and pancreatic cysts, thus distinguishing a separate VHL 
phenotype that was confirmed by subsequent studies and later classified as VHL type 2A.  The 
mechanism of disease suggested by the authors was that “mutant alleles at the VHL locus 
produce different defective proteins; one mutant allele at the VHL locus leads to uncontrolled 
growth of the renal tubular epithelium while another mutant allele at this locus leads to 
uncontrolled growth of the cells of the adrenal medulla” [Glenn et al., 1991].  Some mutant 
alleles, such as a C to T change at nucleotide 712, are thought to cause uncontrolled growth at 
both tissue sites, as evidenced by VHL type 2B families with this mutation who have high 
frequencies of both RCC and pheochromocytoma [Green et al., 1986].  In fact, their risk of 
developing RCC is 32%, which is comparable to VHL type 1 [Maher et al., 1990].   
The major implication from data demonstrating that missense mutations of the VHL gene 
are responsible for the pheochromocytoma-specific phenotype of the disease is that the VHL 
mutant protein must remain full length and be partially functional in order to produce 
pheochromocytoma [Chen et al., 1995].  Accordingly, mutations that result in truncation or 
deletion of a portion of the VHL protein do not result in pheochromocytoma, with the exception 
of deletions of the 3’ untranslated region of the VHL gene that may lead to pheochromocytoma, 
albeit rarely [Chen et al., 1995].  A recent study by Ong et al. [2007] looked more closely at 
VHL-causing missense mutations, subdividing them based upon where in the protein structure 
the amino acid substitution was expected to occur.  Two groups of missense mutations were 
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delineated; those that result in substitution of a surface amino acid (which includes Y98H and 
Y112H) and those that interfere with amino acids deeper in the core of the protein and thus 
disrupt structural integrity [Ong et al., 2007].   The objective of the study was to investigate a 
previous claim that VHL missense mutations associated with pheochromocytoma were more 
likely to involve surface residues [Stebbins et al., 1999].  Indeed, they confirmed the association 
between surface amino acid substitutions and pheochromocytoma predisposition, which will 
allow for further clarification of pheochromocyoma risk [Ong et al., 2007].  However, they found 
that the lifetime risks of retinal angioma, hemangioblastoma, and RCC were not significantly 
different between the two types of mutations [Ong et al., 2007].  Conversely, it was discovered 
that age at first manifestation of VHL disease was significantly earlier, and age-related risks of 
retinal angioma and RCC were higher, in individuals with a truncating mutation (nonsense or 
frameshift) compared to those with deletions or missense mutations that disrupted the structural 
integrity of the VHL gene [Ong et al., 2007].   
The molecular mechanisms underlying pheochromocytoma susceptibility are not yet fully 
understood.  As mentioned above, the best characterized role of the VHL gene product (pVHL) is 
regulating proteolytic degradation of the α subunits of the hypoxia-inducible factor-1 (HIF-1) 
and hypoxia- inducible factor-2 (HIF-2) transcription factors [Cockman et al., 2000; Maxwell et 
al., 1999].  In turn, these transcription factors are active in managing cellular responses to low 
oxygen and regulating transcription of a broad range of target genes implicated in angiogenesis, 
proliferation, and metabolism [Semenza, 2003].  pVHL inactivation stabilizes HIF-1α and HIF-
2α  resulting in activation of target genes that are upregulated in the highly vascularized tumors 
that are a trait of VHL disease.  pVHL binds the HIF α subunits at  a β-domain surface binding 
site and the elongin C protein at a second α-domain surface binding site [Kim and Kaelin, 2003; 
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Ong et al., 2007].  Type 1 and type 2B mutations impair pVHL binding to elongin C, which 
results in decreased pVHL stability and rapid degradation.  On the other hand, type 2A mutations 
map to the HIF-binding site β-domain and do not affect the ability of pVHL to bind to elongin C 
[Clifford et al., 2001].    Although type 2A and type 2B surface missense mutations impair the 
ability of pVHL to regulate the HIF-1 and HIF-2 transcription factors, other VHL mutations 
associated with pheochromocytoma susceptibility retain the ability to regulate HIF, suggesting 
that HIF dysregulation is not solely responsible for pheochromocytoma development in VHL 
disease [Clifford et al., 2001; Hoffman et al., 2001].  Supporting this notion are studies reporting 
that VHL-pheochromocytoma linked mutations are associated with increased JunB expression 
secondary to altered protein kinase C signaling, resulting in failure of apoptosis in adrenal 
medullary progenitor cells in VHL disease and other causes of familial pheochromocytoma [Lee 
et al., 2005].  In addition, the VHL type 2A mutations Y98H and Y112H show only modest 
impairment in HIFα regulation but do not regulate microtubule stability, which is predicted to 
result in chromosome instability [Hergovich et al., 2003; Thoma et al., 2009].  In summary, 
dysregulation of HIF seems to play a role in the development of RCC and pheochromocytoma.  
However, since some VHL mutations that also are associated with pheochromocytoma do not 
interfere with HIF, there must be other mechanism(s) involved in tumor development.  
These genotype-phenotype correlations have been crucial in understanding the genetic 
mechanisms of VHL disease and valuable in presymptomatic diagnosis.  Still, penetrance and 
expressivity of VHL cannot be predicted solely by VHL genotype.  The present study seeks to 
evaluate phenotypic expression of mutations within the same region of the VHL gene that have 
been identified in 2 VHL type 2A families.   
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1.2.2 Founder Effects and Phenotype in Families 1 and 2  
Both the Y112H and Y98H mutations in Family 1 and Family 2, respectively, result in the 
replacement of tyrosine with histidine in exon 1 of the VHL gene.  This nucleotide substitution 
leads to the loss of an AluI endonuclease restriction site [Mulvihill et al., 1997].  While other 
smaller families with pheochromocytoma have been found to have other mutations, such as 
G463T and C712T, the large multigenerational families studied with Y98H and Y112H 
mutations were the main contributing factor in the discovery of the pheochromocytoma-specific 
region of the VHL gene [Crossey et al., 1995; Mulvihill et al., 1997].    
Although these 2 mutations are located within the same exon of the VHL gene, it is not 
unreasonable to believe that they may result in different phenotypic expression of the disease.  
Indeed, Bradley et al. (1999) demonstrated that two different missense mutations in the same 
codon of the VHL gene can cause very distinct clinical phenotypes.  His group investigated a 
large family with a previously unreported T547A mutation in exon 1 of the VHL gene resulting 
in a Tyr112Asn missense mutation (Y112N) in the protein.  The family was characterized by a 
high incidence of RCC and a low incidence of pheochromocytoma; specifically, out of 100 at-
risk family members, there were 13 affected individuals of whom 7 had RCC; other VHL 
manifestations included renal cysts, retinal angioma, and CNS hemangioblastoma [Bradley et al., 
1999].  Of note, there was only one case of pheochromocytoma diagnosed [Bradley et al., 1999].  
Indeed, the Y98N mutation has been associated with RCC [Gnarra et al., 1994].  This is in 
contrast to the Y112H mutation described below which causes a Tyr to His missense mutation 
and is associated with VHL type 2A i.e. pheochromocytoma, but not RCC.  While the Y98H and 
Y112H mutations also result in the replacement of tyrosine with histadine in exon 1, it will still 
be interesting to see if there are any phenotypic differences in these 2 families.  
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The Y98H (Family 2) mutation is well documented in the literature (typically referred to 
as the T505C mutation) and has been established through haplotype analysis as a founder 
mutation originating from the Black Forest region of Germany (i.e. from a different region of 
Germany than Family 1) [Brauch et al., 1995].  Areas of early Pennsylvania were settled to a 
large extent by German immigrants.  The Y98H mutation has been identified in at least 16 VHL 
type 2A families, 2 of which live in Pennsylvania, including Family 2, and all of whom can trace 
their family roots to Germany.  Fourteen of the Y98H families are directly from the Black Forest 
region of Germany and it is believed that Family 2 ancestors emigrated in the early 18th century 
from the Pfalz area to Pennsylvania (Figure 1) [Brauch et al., 1995].  The Pfalz region lies to the 
north of the Black Forest region (Figure 1).  The exact region of Germany from which the other 
Pennsylvanian family emigrated from is unknown.  Brauch et al. [1995] proposed that the Y98H 
mutation “originated and spread in the isolated mountain valleys of the Black Forest.  Due to its 
economic and political status in the 1700s, the Pfalz attracted migratory workers and 
mercenaries.” [Brauch et al.,1995].  They predicted that the mutation originated sometime before 
1700, and was exported to the United States by such Pfalz Family 2 ancestors who immigrated 
from Germany in the 1800s [Brauch et al., 1995].  The data from this study provided crucial 
evidence that “among the 75 different mutations identified by Crossey et al. [1994] and Chen et 
al. [1995] the Y98H mutation is the most tissue-specific VHL mutation with nearly complete 
penetrance by the fourth decade of life” [Brauch et al., 1995].  However, Bender et al. [2001] 
demonstrated that despite high age-related penetrance, the mortality and survival rate of those 
with the Y98H mutation is comparable to those of the general population of Germany.  As 45% 
of German VHL families carry the Y98H mutation, its identification has allowed for 
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presymptomatic genetic diagnosis and genetic counseling in this fraction of the VHL population 
[Brauch et al., 1995].   
The Y112H mutation (Family 1) was discovered a short while after the Y98H mutation, 
by Zbar et al. [1996] in a study examining germline mutations in 469 VHL families from North 
America, Europe and Japan. Further evidence for the association of the Y112H mutation to the 
VHL type 2A phenotype was provided by Chen et al. [1996], when affected members of Family 
1 were tested for a germline mutation of the VHL gene.  Mutation analysis of Family 1 revealed 
the Y112H mutation, which had previously been identified in a much smaller family that only 
contained three affected individuals, all of whom had pheochromocytoma and none of whom had 
RCC [Chen et al., 1996].  These small numbers were insufficient to allow classification of the 
mutation to a specific subtype of VHL type 2.  However, the identification of the mutation in 
Family K, along with another 22 affected patients (19 with pheochromocytoma, 0 with RCC) 
allowed the Y112H mutation to be clearly assigned to VHL type 2A [Chen et al., 1996].   
It is interesting to note that although Family 1 can also trace their roots back to Germany, 
their ancestral area is far removed (approximately 200 miles) from the Black Forest region.  
Family 1 is believed to originate from Leipzig, in the east-central region of the country, in 
contrast to the southwest corner of the country where the Black Forest is located.  Family 1’s 
ancestors migrated to America in 1670 (compared to Family 2 migration in the early 1700s) and 
although members of the clan are scattered throughout the United States, more than 600 
descendents settled in Western Pennsylvania [Tisherman et al., 1993].  The origins of the other 
families identified with Y112H mutation are unknown, and therefore a founder effect for this 
mutation cannot be established at the present time.   
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Although the primary risk of VHL type 2A is pheochromocytoma, the presence of other 
VHL-associated tumors cannot be ignored.  Over a decade ago, Family 1 was known to have 4 
members with retinal angioma and one member with CNS hemangioblastoma, while a larger 
grouping of families (NCI family 3127) that includes Family 2 had 22 members with retinal 
angioma and 4 members with CNS hemangioblastoma  [Chen et al., 1995; Chen et al., 1996].  A 
later study by Bender et al. [2001] compared the frequencies of tumors in Y98H mutation 
carriers from Germany and the United States, which included Family 2 as well as another 
Pennsylvanian family.  While the families clearly share common ancestors, there was marked 
variation in tumor frequencies.  The frequency of pheochromocytoma was similar between 
German and American families (47% and 55%, respectively); however, the frequency of retinal 
angioma was higher in American families (47% vs. 36%) while CNS hemangioblastoma 
occurred more often in German families (41% vs. 9%).  Also, while there was a complete 
absence of RCC in the American families, there were 4 cases in the German families (3%).  The 
authors proposed that these differences may reflect the fact that a gene mutation alone is 
sufficient to cause pheochromocytoma, while both genetic and environmental factors are more 
influential in the development of retinal angioma and CNS hemangioblastoma; they could not 
determine whether the development of RCC in Y98H mutation carriers was a true consequence 
of the mutation or not, given the small numbers of the study and taking into account the annual 
incidence of RCC in the general population in Germany [Bender et al., 2001].  These data will be 
important in comparing VHL type 2A manifestations in 2 families from relatively similar 
environments, and may give us more insight into gene-environment interactions regarding VHL 
type 2A. 
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1.3 MANAGEMENT AND SURVEIILLANCE OF VHL 
1.3.1 VHL Surveillance Recommendations  
Studies of the natural history of VHL showed a life expectancy of 50 years before surveillance 
protocols were established, the main causes of death being the complications of RCC and CNS 
hemangioblastoma [Lamiell, Salazar, Hsia, 1989; Maher et al., 1990; Neumann et al., 1993].  
Morbidity and mortality is alleged to have decreased due to syndrome delineation, earlier 
diagnosis, improved imaging techniques, and improvements in therapy [Lonser et al., 2003].  
Surveillance is felt to be critical not only in detecting new lesions at an early stage, but also in 
monitoring small asymptomatic lesions for progression.  Surveillance is focused primarily on 
hemangioblastoma (including retinal angioma), RCC and pheochromocytoma because they are 
the three manifestations most often resulting in severe disability or death [Chan-Smutko, Plon, 
Iliopoulos, 2009].  Regular clinical monitoring by a physician or medical team familiar with the 
spectrum of VHL disease is required in 3 groups of patients: those with known VHL, those 
known to have a VHL disease-causing mutation, and those at-risk by inheritance but who have 
not yet undergone DNA testing [Schimke, Collins, Stolle, 2000].  Screening recommendations 
are adapted to the individual, taking into account previously diagnosed disease, the VHL disease 
spectrum, and prior VHL manifestations in other family members [Chan-Smutko, Plon, 
Iliopoulos, 2009].   
Molecular genetic testing is indicated in all individuals with a confirmed or suspected 
diagnosis of VHL [Rasmussen et al., 2006].  Testing is performed through sequence analysis 
and/or deletion analysis.  Sequence analysis scans all 3 exons for point mutations and small 
deletions or insertions in the VHL gene, which account for approximately 72% of all VHL 
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mutations [Stolle et al., 1998].  Partial or complete gene deletions account for approximately 
28% of all VHL mutations and can be detected through various methods [Banks et al., 2006; 
Stolle et al., 1998].  A positive result is confirmed when a mutation is identified in at least one 
copy of the VHL gene.  Once a positive result is identified in a family, single-site analysis can be 
offered to other family members.  A negative result means that neither copy of the VHL gene is 
altered; since the margin of error for this test is typically under 1-2%, this is considered a true 
negative result.  However, somatic mosaicism for a de novo VHL germline mutation cannot be 
ruled out in individuals with VHL manifestations who do not meet strict diagnostic criteria and 
who do not have a detectable VHL germline mutation [Schimke, Collins, Stolle, 2000].  
Additionally, individuals tested prior to the year 2000 using linkage analysis can consider being 
re-tested as improved techniques are more reliable and may reveal prior test results as false 
negatives.  A referral for genetic counseling is critical for individuals undergoing testing in order 
to fully understand the implications of testing and correct interpretation of results.   
Interestingly, the literature does not yet distinguish clinical surveillance recommendations 
by VHL subtype.  The only pheochromocytoma-specific recommendation is somewhat out of 
date, as it antedates plasma metanephrine testing and instead recommends annual blood pressure 
monitoring supplemented by annual measurement of urinary catecholamine metabolites 
beginning at age 5 years in families with a high incidence of pheochromocytoma [Schimke, 
Collins, Stolle, 2000].  Overall surveillance protocols for monitoring high-risk VHL patients 
have been developed by several groups; what follows are the recommendations of the National 
Institutes of Health (NIH) group [Choyke et al., 1995] and the VHL Family Alliance.  Family 
members who had a 50% risk of VHL prior to genetic testing, but are found not to have inherited 
the mutation, do not need further clinical monitoring. To summarize, more extensive screening 
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and monitoring for pheochromocytoma appears both sensible and necessary for VHL type 2A 
families.      
 
 
Table 2.  VHL Surveillance Recommendations  
Age (y) Recommendation 
Infancy (birth-23 months) - Annual physical examinations including 
retinal examination  
2-10 - Annual physical and retinal examination  
- Urinary or plasma catecholamines every 1-2 
years 
- Annual abdominal ultrasound from 8 years or 
earlier if indicated. Abdominal MRI or MIBG 
scan only if biochemical abnormalities found   
- Audiology assessment every 2-3 years, or 
annually if any hearing loss, tinnitus, or vertigo  
11-19 - Retinal examination every 6 months  
-Annual physical examination and neurological 
assessment  
-24-hour urine catecholamine and meta-
nephrine collection. Abdominal MRI or MIBG 
scan only if biochemical abnormalities found  
- Ultrasound of abdomen. If abnormal, MRI or 
CT of abdomen, except in pregnancy  
- Annual MRI with gadolinium of brain and 
spine  
- Audiology assessment every 1-2 years  
20+ - Annual physical and retinal examination 
- Annual CT scan of the abdomen  
- 24-hour urine or plasma catecholamine and 
metanephrine collection. Abdominal MRI or 
MIBG scan if biochemical abnormalities found 
- Annual MRI with gadolinium of brain and 
spine (except during pregnancy)  
- Audiology assessment every 2 years 
- MRI of internal auditory canal (IAC) every 2 
years  
60 If no evidence of VHL, change MRI of brain 
and spine to every 3 to 5 years; CT of abdomen 
every other year  
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The classic symptom triad of pheochromocytoma is episodic headache, sweating, 
palpitations and/or tachycardia - symptoms which can be variously attributed to panic attack, 
allergy, and even (when occurring during sleep) nightmare.  Blood pressure monitoring is also 
important in screening.  Although in the general population pheochromocytoma accounts for less 
than 0.2% of patients with hypertension, in patients with pheochromocytoma, sustained or 
episodic hypertension can be the first sign of tumor, therefore such severe hypertension should 
always prompt diagnostic investigation for possible pheochromocytoma.  It is essential to keep in 
mind, however, that the majority of patients with pheochromocytoma have no history of 
hypertension [Bravo, 1991; Manger and Gifford, 2002; Stein and Black, 1991].  In hereditary 
pheochromocytoma, tumors present at a younger age, are more often multiple or extraadrenal, 
are less likely to secrete epinephrine, and are less likely to be associated with symptoms or 
biochemical evidence of catecholamine production [Eisenhofer et al., 1999; Tisherman et al., 
1993; Walther et al., 1999].   
Biochemical screening is the standard of care in patients at risk for hereditary 
pheochromocytoma.  Plasma metanephrine testing is currently the most sensitive test and is 
therefore the test of choice.  Although the measurement of 24-hour urine catecholamines and 
metanephrines is more specific (98%), plasma metanephrines testing is more sensitive because it 
captures small amounts of metanephrines which are the breakdown products produced 
continuously by the metabolism of catecholamines, as opposed to catecholamines themselves 
which are only secreted intermittently during acute hypertensive episodes (Figure 2) [Guller et 
al., 2006; Lenders et al., 2002].  In addition, plasma metanephrine testing is simple to perform, 
has few causes of false positive results, and has a high predictive value in excluding 
pheochromocytoma except in patients with ultra-rare, strictly dopamine-secreting tumors [Sawka 
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et al., 2004].  As with urine screening, a drawback of plasma metanephrine testing is that it may 
not be reliable for the detection of microscopic recurrent or metastatic disease or very small 
tumors (<1cm) [Lenders et al., 2002, Young and Kaplan, 2009].  
 
 
Figure 2.  Catecholamine Metabolism Pathway  
http://www.endotext.org/adrenal/adrenal34/adrenal34.htm 
 
Chromogranin A and VMA (vanillylmandelic acid) are 2 other biochemical tests used in 
diagnosis and management of pheochromocytoma.  VMA is a metabolic product of 
catecholamine metabolism (Figure 2) and chromogranin A is an intragranular binding protein.   
Following synthesis (Figure 2) catecholamines are actively accumulated by the dense-core 
subcellular chromaffin granules of the adrenal medulla and of pheochromocytoma tissue,  by an 
ATP-dependent process coupled to the magnitude of the electrochemical proton gradient across 
the chromaffin granule membrane [Johnson, Carty & Scarpa, 1982].  Once accumulated into the 
chromaffin granule, catecholamines are stored in very concentrated form by binding to the 
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intragranular protein, chromogranin A.  Blood levels of Chromogranin A are increased in 80% of 
patients with pheochromocytoma [Cotesta et al., 2005] allowing its use as tumor marker.  
Although Chromogranin A it is not specific for pheochromocytoma, it is routinely measured 
prior to pheochromocytoma surgery and in surveillance after surgery, to facilitate detection of 
metachronous disease.   Because of its serious risks, which include heart attack and stroke if left 
untreated, all patients diagnosed to have pheochromocytoma move promptly towards resection.  
Radiologic tests are routinely used to localize pheochromocytoma after biochemical diagnosis.  
Noncontrast CT of the abdomen and pelvis is usually performed first because it is cost effective, 
widely available, and because the differential density of adrenal tissue on the noncontrast views 
has utility in distinguishing adrenal cortical tumor from other adrenal tumor types (Laursen and 
Damgaard-Pedersen, 1980; Young and Kaplan, 2009).  Although about 10% of 
pheochromocytomas are extra-adrenal, about 95% of these occur within the abdomen and pelvis 
[Bravo, 1994].  CT has been the predominant imaging technique since 1977, with a sensitivity of 
94% and a specificity of 97% [Goldstein et al., 1999].  MRI has been available since 1985 and is 
particularly useful in distinguishing pheochromocytoma from other adrenal masses, with a 
specificity of almost 100%, and a sensitivity of 83% [Goldstein et al., 1999]. Features of 
malignancy on CT or MR imaging include heterogeneity, central necrosis, and local or vascular 
invasion; size > 6 cm has also been shown to predict malignancy [Sturgeon and Kebebew, 2004].  
In patients with radiologically occult disease, suspected synchronous or metastatic disease, or for 
whom pheochromocytoma is clinically suspected but catecholamine measurements are in the 
normal range, 123-I-metaiodobenzylguanidine (MIBG) scintigraphy is then indicated [Guller et 
al., 2006]; again, 35% of patients with VHL pheochromocytoma have no symptoms, normal 
blood pressure, and normal catecholamine tests [Walther et al., 1999].  MIBG is a substituted 
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amine resembling norepinephrine, which is taken up by adrenergic tissue.  In patients with 
pheochromocytoma >10 cm in size, who are thus at greatly increased risk for malignancy, and in 
patients with extra-adrenal paraganglioma, who are thus at risk for synchronous disease [Clarke 
et al., 1998] MIBG scanning is recommended to survey the body for metastatic disease or 
multiple tumors.  [Lee and Duh, 2008; Whalen, Althausen, Daniels, 1992].   
1.3.2 Management of Pheochromocytoma, Hemangioblastoma, and Retinal Angioma  
Two decades ago, medical students were taught that the most common presentation of 
pheochromocytoma was sudden death at an early age from unexplained causes.  Although 
surgical resection of pheochromocytoma carried significant mortality in the past, it is now the 
standard treatment for any diagnosed pheochromocytoma.  [Lonser et al., 2003; Walther et al., 
1999].  Due to the severe risks of untreated pheochromocytoma including heart attack, heart 
failure, stroke, kidney failure and cognitive decline, surgery is generally considered urgent and 
with high clinical priority.  Before surgery, however, careful pharmacological alpha-adrenergic 
blockade and intravascular volume repletion is almost always required [Lonser et al., 2003].  
About 17% of patients with pheochromocytoma also have an associated cardiomyopathy 
diagnosed by preoperative echocardiogram, and which resolves with tumor resection.  The 
treatment of pheochromocytoma is resection with intent to cure, which may usually be readily 
accomplished laparoscopically for radiologically benign-appearing tumors < 6 cm in size.  In 
patients with VHL pheochromocytoma, cortical-sparing adrenalectomy has been shown to result 
in better long-term corticosteroid independence, [Baghai et al., 2002], thus in VHL the preferred 
initial surgical approach today is laparoscopic partial adrenalectomy [Walther et al., 2000].  
Partial adrenalectomy, however, is associated with increased risk of metachronous ipsilateral 
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recurrence.  Any suspected malignant pheochromocytoma should be entirely resected entirely 
using open (non-endoscopic) en bloc technique.   
Hemangioma of the CNS is the most common tumor in VHL, affecting 60-80% of 
patients [Neumann et al., 1993; Wanebo et al., 2003].  Although these tumors are benign, their 
local growth can cause significant morbidity: hemangiomas can arise anywhere along the 
craniospinal axis and are often associated with edema, cysts, or both.  Common locations are the 
spinal cord and cerebellum, followed by the brainstem, lumbosacral nerve roots, and 
supratentorial region [Lonser et al., 2003].  Symptoms related to hemangioblastoma of the brain 
and spinal cord vary depending on tumor location and size, and presence of associated edema or 
cysts, [Chan-Smutko, Plon, Iliopoulos, 2009].  Most hemangioblastomas of the craniospinal axis 
can be safely and completely excised [Malis, 2002; Lonser et al., 2003; Weil et al., 2003].   
Because CNS hemangioma can grow at several sites simultaneously, new lesions can arise at any 
time, the growth pattern can be irregular and unpredictable, and the surgery itself can have 
morbidity, resection is generally deferred until the onset of symptoms [Lonser et al., 2003; 
Wanebo et al., 2003; Weil et al., 2003].  Small craniospinal hemangioblastomas (<3 cm) that are 
not associated with a cyst have recently been treated with stereotactic radiosurgery, but the long-
term effects of this treatment have not yet been determined [Lonser et al., 2003].   
Retinal angioma is a frequent occurrence in VHL, seen in as many as 60% of patients 
who are screened for it [Dollfus et al., 2002; Webster, Maher, Moore, 1999].  Angiomas arise in 
the retinal periphery, on or near the optic disc, or both [Lonser et al., 2003].  They are often 
multifocal and bilateral (about 50%) [Lonser et al., 2003].  Early diagnosis and treatment of 
retinal angioma, which now can include radiotherapy, can prevent visual loss or blindness, with 
most peripheral retinal tumors responding to laser photocoagulation or cryotherapy [Lonser et 
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al., 2003].  Tumors of the optic disc should be monitored without treatment because of the 
damage that some treatments including photocoagulation can cause [Lonser et al., 2003].  All 
patients with VHL thus require annual retinal exam, but not all patients are able to comply.    
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2.0  METHODS 
Under a full University of Pittsburgh Institutional Review Board-approved protocol (IRB # 
09010261), we retrospectively reviewed the available records of patients known to have VHL in 
both studied kindreds (Family 1, n=49; Family 2, n=65).  We identified all patients diagnosed 
with VHL pheochromocytoma to date, and obtained extensive family history in patients 
presenting here for management of inherited pheochromocytoma management.  For Family 1, we 
also received extensive heritage pedigree materials from Wendy S. Rubinstein MD, Samuel E. 
Tisherman MD, and Marlin A. Field (author of Family 1 genealogy book) [Field, 1993].  From 
these data we constructed de novo pedigrees for both families. We then used clinical documents, 
partial heritage pedigrees, and patient interview data to verify pedigree and clinical findings.   
2.1 DESIGN 
This is a retrospective study to investigate possible differences in the expression of VHL type 2A 
disease, particularly with regard to pheochromocytoma, between 2 large multigenerational 
kindreds who reside in Western Pennsylvania with different disease-causing missense mutations 
in the VHL gene.  Many members of both families are currently followed by the Endocrine 
Surgery division at the University of Pittsburgh Medical Center (UPMC).  One family (Family 1) 
was originally identified and laboriously tabulated by a late University of Pittsburgh internist 
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(S.E.T.).  Some members of the other family (Family 2) have previously been partially described 
by the NIH (NCI family 3127) [Glenn et al., 1991].     
2.2 PEDIGREE CONSTRUCTION 
Pedigrees were constructed using Progeny Clinical 7.6.03 (Serial # 710390) Genetic Data 
Management Software (Copyright ©2007 Progeny Software, LLC, South Bend, Indiana).   
 
 
2.2.1 Family 1 
 
Many sources of data were used in constructing the pedigree for Family 1, but the majority of 
information was from the extensive but previously uncollated paper records of Dr. Samuel 
Tisherman Sr., who first described the family [Tisherman, Gregg, Danowski, 1962; Tisherman et 
al., 1993].  These heritage records contained extensive handwritten notes taken during colorful 
family reunions organized by Dr. Tisherman, in which he (and his family members) would take 
the blood pressure of Family 1 members to assess for hypertension.  He also documented details 
of medical and family histories, and distributed research questionnaires regarding VHL and 
pheochromocytoma.  Multiple sketched pedigrees were combined to create three separate 
branches of the family based on the descendents of the three original siblings thought to be 
carriers for VHL, namely individuals II-3, II-4, and II-5.    
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We also received extensive pedigree materials from Dr. Wendy S. Rubinstein, who 
worked closely with Dr. Tisherman before his death.  This included a small “VHL/Pheo Study” 
Microsoft Access database detailing demographics, medical history, cancer history, testing, 
surgeries and hospitalizations of selected members of Family 1 (established by Sean Davis, MD, 
PhD).  Additionally, our computer support personnel were able to access and display an outdated 
Progeny file, previously compiled by Drs. Tisherman and Rubinstein, of a pedigree for the II-5 
branch of Family 1.  This information was received after completion of our own Progeny 
database, and therefore was used very effectively to verify our own data.  Another source of 
information used to verify relationships was a genealogy book about Family 1 [Field, 1993] 
which Dr. Carty purchased from the author.  The book did not include any medical information 
but was very useful in obtaining dates of birth and death and family relationships.  Based on 
these data and on clinical data from our own Family 1 patients, we then laboriously revised and 
expanded the final Family 1 pedigree (Figure 3).   
 
2.2.2 Family 2 
Based on our own clinical data, we constructed de novo a regional pedigree for Family 2.  Under 
a full IRB-approved protocol (# 09010261) and always complying with HIPAA regulations to 
protect patient privacy, we accessed additional sources of information including pedigrees of 
family branches that were completed through their genetic counseling consultation at the UPMC 
Cancer Genetics Program, extensive phone conversations with identified historians of Family 2, 
and medical records provided to us by kindred members.  
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2.3 CONTACTING PATIENTS 
Contacting selected members of both families was very necessary to this study.  Our clinical data 
did not encompass all members of Families 1 and 2 known to be affected, nor did it include all 
medical care of affected individuals related to their VHL diagnosis; most individuals live a 
distance from Pittsburgh and thus receive care at other institutions, or in some cases no care.  
When contacting patients, a brief description of the study was given, and interested participants 
were emailed or mailed a medical records release and a copy of the informed consent to sign and 
return. They were encouraged to forward the email to other family members who might be 
interested in the study, but the decision to do so was their own.  Returned informed consent 
documents were filed.  Signed medical records release forms were faxed to the institutions 
specified by study participants at which they had received care related to their diagnosis of VHL. 
Some members of both Family 1 and Family 2 were also evaluated at the UPMC Endocrine 
Genetics Clinic program, which is co-Directed by Dr. Carty, where medical and family 
information was again verified.    
2.4 PHENOTYPIC DATA  
From all the available data, study patients were coded as affected or unaffected with VHL or its 
manifestations, by use of 3 categories of veracity:  
A) Robust or confirmed genetic, medical and/or pathologic documentation i.e. 
paper records;  
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B) Status suspected e.g. by oral history (includes information gleaned from 
Cancer Genetics pedigrees); or  
C) Status suspected but no other confirmatory information available.   
All family members with known pheochromocytoma (pheo), hemangioblastoma (HB), 
retinal angioma (RA), or RCC were logged into a database.  Based on all category A and B data, 
detailed pedigree analysis was used to identify obligate carriers as well as to construct age-
related probability curves for the major manifestations of VHL type 2A.   
Patients with category A data in support of VHL were considered informative and their 
data were used for the determination of differences between the 2 kindreds in regards to VHL 
type 2A pheochromocytoma phenotype.  We then compared clinical parameters (age of first 
pheo, development of metachronous tumors, time to new occurrence of pheo, diagnosis by 
symptoms or screening, norepinephrine/epinephrine secretion status pre-operatively, biochemical 
cure, demise from disease [DOD]) and pathologic parameters (site, laterality, size, weight, 
multifocality, recurrence, and metastasis) for each of 100 pheos with category A data (Family 
1=55, Family 2= 45) among the 2 kindreds.  We also used level B pheo data for analysis of: age 
of diagnosis at first pheo, diagnosis by symptoms or by screening, development of metachronous 
tumors, and biochemical cure.  This information allowed for evaluation of 30 additional pheos 
with respect to these 4 categories (Family 1= 10; Family 2 = 20). Mean follow-up was 13.1 y for 
Family 1 (range 1.75 -38.5 y) and 12.3 y for Family 2 (range 0.1-34 y).   
  31 
2.5 STATISTICAL ANALYSIS  
Fisher’s exact test was used to compare categorical data (i.e. presence or absence of 
pheochromocytoma, hemangioblastoma, retinal angioma, and RCC) and student’s t-test was used 
to compare continuous data (i.e. pheo parameters) between the 2 families.  Online statistical 
calculators were used to determine p values 
(http://graphpad.com/quickcalcs/ttest1.cfm?Format=SD; 
http://faculty.vassar.edu/lowry/odds2x2.html).  Significance was set at 0.05, and p values were 2-
tailed.    
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3.0  RESULTS 
3.1 VHL DIAGNOSIS, DEMOGRAPHICS AND PENETRANCE 
Family 1 has 3 branches with VHL type 2A, consisting of 108 individuals over 7 generations; the 
pedigree is seen in Figure 3.  In Family 1, 49/108 members (45.4%) appear to be affected with 
VHL to date.  Additionally, based on category C evidence, another 2 Family 1 individuals (III-2, 
IV-2) are suspected to have the condition (47.2%).   
 
 
Figure 3.  Family 1 Pedigree  
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Family 2 has 131 individuals over 6 generations as seen in the pedigree of Figure 4.  Of these, 65 
(49.6%) appear to be affected with VHL type 2 to date (Figure 4).  An additional 6/131 Family 2 
individuals (II-3, II-4, II-5, III-1, III-2, III-3) are suspected to have VHL based on category C 
data (54.2%).   
Gender distribution of patients with VHL did not appear to differ between families: 29/49 
(59.2%) of affected Family 1 members were male, and 35/65 (53.8%) of affected Family 2 
members were male.  Our data thus confirm an autosomal dominant inheritance pattern of VHL 
type 2A in both of the families in this study.   
 
 
 
Figure 4.  Family 2 Pedigree  
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VHL was diagnosed as described in Methods (Section 2.4) and this is illustrated 
schematically in Figure 5.  In Family 1, the assignment of VHL diagnosis was based upon 
clinical and/or genetic data for 35/49 patients (71.4%), was proven by genetic analysis alone in 
8/49 clinically unaffected patients (16.7%), and was determined by obligate carrier status in 6/49 
kindred members (12.5%).  Clinical data were assessed as category A in 31/35 (88.6%) 
individuals, of whom 25 had confirmatory genetic testing; clinical data was category B in 4/35 
(11.4%) patients, of whom 2 reportedly had positive mutational analysis which we could not 
confirm for this study.  Therefore in Family 1, and with the caveat that the study design did not 
allow for prospective genetic testing of all patients at risk, VHL has been asymptomatic to date 
in 14/49 identified kindred members (28.6%), and the observed penetrance of VHL was 71.4%.   
 
 
 
Figure 5.  Schematic of VHL Type 2A Kindred Analysis  
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The observed diagnostic mechanisms for VHL were surprisingly similar between the 2 
families.  In Family 2, VHL diagnosis was based upon clinical and/or genetic data for 47/65 
patients (72.3%), by genetic analysis alone in 10/65 clinically unaffected patients (15.4%), and 
8/65 patients were obligate carriers (12.3%) (Figure 5).  Family 2 clinical data was assessed as 
category A in 24/47 (51.0%) patients of whom 7 had genetic testing and as category B in 23/47 
(48.9%) patients of whom 4 reportedly had genetic testing which we could not confirm.  Thus in 
Family 2, VHL has been asymptomatic to date in 18/65 kindred members (27.7%) and the 
observed penetrance of VHL in Family 2 was 72.3%, which is nearly identical to that observed 
for Family 1 (71.4%).  These data must again be viewed against the limitation that some kindred 
members have not received formal evaluation and many members do not have consistent follow-
up.  The issue of incomplete evaluation is of particular concern for Family 2, as we have 
anecdotally observed more fiscal/health insurance stress and greater social barriers to care among 
Family 2 members.  This observation is reflected by a lower rate of confirmed genetic mutational 
analysis in Family 2 (30.8% of family members with confirmed VHL) than Family 1 (87.8% of 
family members with confirmed VHL), but also may reflect the fact that the majority of genetic 
testing that occurred in Family 1 was done under a prior research protocol and was thus free of 
charge to participants.   
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3.2 CLINICALLY SIGNIFICANT VHL TYPE 2A 
3.2.1 PATTERNS OF VHL TYPE 2A MANIFESTATION AMONG CLINICALLY 
AFFECTED KINDRED MEMBERS  
Category A clinical features of VHL were documented in 31/35 (88.6%) symptomatic 
informative Family 1 members and in 24/47 (51.2%) symptomatic informative Family 2 
members (Figure 5).  The remaining clinical features in each family were classified as category 
B.  Table 3 compares the type of initial manifestation of VHL type 2A by family.  As may be 
seen, patients in Family 2 were somewhat more likely to have hemangioblastoma as the initial 
manifestation than did Family 1 members (p = 0.07), whereas Family 1 members appeared more 
likely to be diagnosed concurrently with pheochromocytoma and retinal angioma together as 
initial manifestations (p = 0.07), but these differences did not reach significance.  Otherwise, the 
initial diagnosed tumor type(s) were quite similar between the 2 families.   
Interestingly, one member of Family 1 (V-1) was diagnosed with RCC at age 35, but she 
derived from a branch of the family not known to be affected with VHL type 2A in any way.  
Because there was partial lack of data regarding the VHL status of her 3 prior generations, it 
could not be authoritatively determined whether her RCC was related to VHL type 2A or was 
sporadic, but our best estimate was that it was unrelated and sporadic thus she was not included 
in pedigree analysis.  It is of course possible that her diagnosis was related to VHL type 2A.    
She passed away 2 years later from metastatic disease.    
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Table 3.  Initial VHL Type 2A Manifestations in Clinically Affected Kindred Members  
 
Family 1  
(n=35) 
Family 2  
(n=47) p value 
Pheo 26 (74.3%) 33 (70.2%) 0.81 
HB 1 (2.9%) 8 (17.0%) 0.07* 
RA 5 (14.3%) 6 (12.8%) 1.00 
RCC 0 0 1.00 
Pheo+HB 1 (2.9%) 3 (6.4%) 0.63 
Pheo+RA 3 (8.6%) 0 0.07* 
HB+RA 0 1 (2.1%) 1.00 
HB+RA 0 1 (2.1%) 1.00 
Pheo, pheochromocytoma; HB, hemangioblastoma; RA, retinal 
angioma; RCC, renal cell carcinoma  
p < 0.05 = significant  
 
Data on the lifelong manifestations of VHL type 2A among clinically affected kindred 
members are given in Table 4.  The 2 families appear to be very much alike in regard to lifelong 
manifestations, with the main differences being related to rates of retinal angioma and 
hemangioblastoma.  There were 13 members with known retinal angioma (37.1%) in Family 1, 
compared to 9 members in Family 2 (19.1%) (p = 0.08), and Family 1 members were more likely 
than Family 2 members to have been diagnosed with both retinal angioma and 
pheochromocytoma (14.3% vs. 2.1%) (p = 0.08), but these differences did not reach significance. 
Although Family 2 members appeared both more likely to have hemangioblastoma alone (6.4%, 
vs. 0), and in conjunction with other type 2A manifestations, the observed differences were not 
significant. Conversely, Family 1 had a somewhat higher rate of documented 
pheochromocytoma, with a total of 30 affected members (85.7%) compared to Family 2 with 37 
total members affected (78.7%).  It is interesting to note that Family 1 members appeared 
somewhat more likely to have multiple manifestations; 5.7% of Family 1 members had 
pheochromocytoma, hemangioblastoma and retinal angioma, compared to 2.1% of Family 2 
members (p = 0.57).  One member of Family 1 (VI-2) was even diagnosed with all 4 type 2A 
manifestations.     
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Table 4.  Cumulative VHL type 2A Manifestations Among Clinically Affected Kindred Members  
 
Family 1  
(n=35) 
Family 2 
(n=47) 
p value 
(univariate) 
Pheo+HB+RA+RCC 1 (2.9%) 0 0.43 
Pheo+HB+RA 2 (5.7%) 1 (2.1%) 0.57 
Pheo+HB 3 (8.6%) 7 (14.9%) 0.50 
Pheo+RA 5 (14.3%) 1 (2.1%) 0.08* 
Pheo only 19 (54.3%) 28 (59.6%) 0.66 
Total Pheo 30 (85.7%) 37 (78.7%) 0.56 
HB+RA 0 1 (2.1%) 1.00 
HB only 0 3 (6.4%) 0.26 
Total HB 6 (17.1%) 12 (25.5%) 0.43 
RA+RCC 0 1 (2.1%) 1.00 
RA only 5 (14.3%) 5 (11.0%) 0.74 
Total RA 13 (37.1%) 9 (19.1%) 0.08* 
Total RCC 1 (2.9%) 1 (2.1%) 1.00 
Pheo, pheochromocytoma; HB, hemangioblastoma; RA, retinal angioma; RCC, 
renal cell carcinoma  
p < 0.05 = significant 
 
There were only 3 cases of RCC observed.  As discussed above, in one Family 1 woman 
(V-1) RCC was likely sporadic.  RCC was also noted in 1 Family 2 woman with VHL (IV-8) 
who developed it at age 44, and in one Family 1 woman with VHL (VI-2) who developed it at 
age 42.  Both women had VHL type 2A manifestations prior to their diagnosis of RCC;  RA in 
the woman from Family 2, and pheo and RA in the woman from Family 1.  In this study, 
therefore, the rate of RCC observed among all 82 individuals at risk from both families was thus 
2/82 = 2.4%.   
 
Because Family 1 has been described multiple times in the literature over the years, Table 
5 displays the rates of pheochromocytoma reported over the years as new diagnoses were made.  
Obligate carriers and DNA positive individuals were not included in the prior study data; the 
rates given here are solely those of clinically affected individuals.  We see that in Family 1, 
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reported pheochromocytoma rates have been surprisingly constant, ranging from 77.4% to 
88.9%, and this is in spite of the fact that not all family members were thoroughly evaluated, 
especially in early years when elevated blood pressure was often used as a primary means of 
pheochromocytoma screening.   
 
 
Table 5.  Reported Rates of Pheochromocytoma in Family 1: 1962-Present  
 
Clinically 
Affected Pheo  Pheo Rate (%)  
Tisherman, 19621 9 8 88.9 
Tisherman, 19932 19 16 84.2 
Mulvihill, 19973 31 24 77.4 
Current Study 35 30 85.7 
1 Tisherman SE, Gregg FJ, Danowski TS. JAMA 182: 152-156.  
2 Tisherman SE, Tisherman BG, Tisherman SA, et al. Arch Intern Med 153: 
2550-2556.  
3 Mulvihill JJ, Ferrell RE, Carty SE, et al. Arch Intern Med 157: 1390-1391.  
 
3.2.2 TUMOR-SPECIFIC PENETRANCE OF VHL TYPE 2A MANIFESTATIONS 
AMONG INFORMATIVE CARRIERS  
Overall VHL penetrance calculations (above) were based on kindred members with VHL 
diagnosis by clinical manifestations, genetic analysis, and/or obligate carrier status.  To 
determine tumor-specific penetrance, we decided to examine only those VHL type 2A carriers 
who were informative, and this analysis included not only category A data but also specific 
category B data when appropriate. This objectivity also necessarily excluded the majority of 
individuals in early generations in both families, mainly generations I, II and most of generation 
III.  Some individuals in later generations were also excluded when no information was 
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available.  Therefore, the total number of informative carriers for each manifestation of Type 2A 
VHL differs by tumor type, as is seen in Table 6.  Table 6 also gives the cumulative (lifetime) 
penetrance among clinically affected family members.    
 
 
Table 6.  Penetrance of VHL Type 2A Manifestations Among Informative Carriers  
 
Penetrance by age 50 Cumulative Penetrance  
Family 1 Family 2 
p 
value Family 1 Family 2  
p 
value 
Pheo 
(n=42;56) 
24 (57.1%) 37 (66.1%) 0.40 30 (71.4%) 37 (66.1%) 0.66 
HB 
(n=39;53) 
5 (12.8%) 11 (20.8%) 0.41 6 (15.4%) 12 (22.6%) 0.44 
RA 
(n=39;54) 
12 (30.8%) 7 (12.9%) 0.04* 13 (33.3%) 9 (16.7%) 0.08* 
RCC 
(n=39;53) 
1 (2.6%) 1 (1.9%) 1.00 1 (2.6%) 1 (1.9%) 1.00 
Pheo, pheochromocytoma; HB, hemangioblastoma; RA, retinal angioma; RCC, renal cell carcinoma  
p < 0.05 = significant 
 
 Tumor- specific penetrance by age 50 of VHL type 2A manifestations among informative 
carriers was similar between the 2 studied families, with the exception of retinal angioma.  By 
age 50, retinal angioma had been diagnosed in at least 30.8% of Family 1 members, as opposed 
to 12.9% of Family 2 members (p=.04), and over a lifetime, retinal angioma was known to be 
present in at least 33.3% of VHL carriers in Family 1, and in only 16.7% of VHL carriers in 
Family 2.  The penetrance of hemangioblastoma appeared to be somewhat higher in Family 2 
both by the age 50 (20.8% vs. 12.8%) and over a lifetime (22.6% vs. 15.4%) but without 
reaching statistical significance.  Pheochromocytoma was the most penetrant manifestation in 
both families; although not statistically significant, a higher proportion of Family 2 members 
were diagnosed with pheochromocytoma by age 50 (66.1% vs. 57.1%), while penetrance of 
pheochromocytoma was higher in Family 1 over a lifetime (71.4% vs. 66.1%).   
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3.2.3 CUMULATIVE PROBABILTY OF VHL TYPE 2A MANIFESTATIONS BY AGE 
OF DIAGNOSIS  
Figures 6-9 show the cumulative probabilities for pheochromocytoma, hemangioblastoma, and 
retinal angioma, respectively, based on age of first diagnosis for each tumor type.  RCC was 
excluded because of the small number of cases.  Ages of first diagnosis of hemangioblastoma 
and retinal angioma were more likely to be by self-report (category B data), as was the case for 
2/6 individuals with hemangioblastoma and 4/13 individuals with retinal angioma in Family 1, 
and for 3/11 individuals with hemangioblastoma and 4/6 individuals with retinal angioma in 
Family 2.  The above numbers reflect ages of first diagnosis which were unable to be verified in 
1 case of hemangioblastoma and 3 cases of retinal angioma in Family 2.  Age at first diagnosis of 
pheochromocytoma in Family 1 ranged from 6-72 years, and from 8-47 years in Family 2.  As 
may be seen from Figure 6, Family 2 consistently had a higher probability for 
pheochromocytoma diagnosis at each age range up to 50 years.  While all cases of 
pheochromocytoma were diagnosed by age 50 in Family 2, in Family 1 pheochromocytoma was 
diagnosed as late as 72 years of age.   
  42 
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Figure 6.  Cumulative Probability by Age of Diagnosis of First Pheo  
 
Age at first diagnosis of hemangioblastoma in Family 1 ranged from 12-56 years of age, 
and from 9-79 years of age in Family 2.  Again, Family 2 had a higher probability of being 
diagnosed with hemangioblastoma at each age range, as shown in Figure 7.  All cases of 
hemangioblastoma were diagnosed by age 60 in Family 1, whereas in Family 2 
hemangioblastoma was diagnosed as late as 79 years of age.   
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Figure 7.  Cumulative Probability by Age of Diagnosis of First HB 
 
The range of age at diagnosis of first retinal angioma was 10-55 years of age in Family 1, 
and 23-55 years of age in Family 2.  Shown in Figure 8, Family 1 consistently had a higher 
probability of being diagnosed with retinal angioma at each age range.  All cases of retinal 
angioma were diagnosed by age 60.    
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Figure 8.  Cumulative Probability by Age of Diagnosis of First RA 
 
3.3 EXPRESSION PATTERNS OF PHEOCHROMOCYTOMA  
We were able to include a total of 30 individuals from Family 1 and 33 individuals from Family 
2 in the analysis of expression patterns of pheochromocytoma, representing a total of 130 
pheochromocytomas (which were interestingly distributed as 65 pheochromocytomas from each 
family) (See Appendix B for full data set).  Of these, 30 data sets included category B data i.e. 
based on patient report (Family 1, n=10; Family 2, n=20).   The clinical parameters examined 
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included: age at first pheochromocytoma diagnosis, development of metachronous tumors, time 
to recurrence, diagnosis by symptoms or screening, and hormonal secretion status pre-op. 
Pathological parameters included: size, weight, laterality, extraadrenal location(s), and 
multifocality (for synchronous tumors). Pheochromocytoma data were also examined by 
measures of morbidity and mortality, which included recurrence, metastasis, biochemical cure 
with resection and individuals who died of disease (DOD).  Not all pheochromocytomas were 
informative for each parameter measured, thus the specific n is denoted under each category in 
Table 7.   
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Table 7.  Comparison of Pheo Parameters Between VHL Type 2A Families  
 Family 1 Family 2 p value  
Clinical Parameters  
 
Age First Pheo Dx  
(n=30;33) 28.8 19.7 0.02* 
 
Dx by Symptoms     
(n=52;49) 42 (80.8%) 33 (67.3%) 0.17 
 
Tumor Secreted Only 
Norepinephrine  
(n=27;33) 19 (70.4%) 16 (48.5%) 0.12 
 
Metachronous Pheo    
(n=65;65) 21 (32.3%) 13 (20.0%) 0.16 
 
Time to Recurrence (y) 
(n=21;12) 7.8 12.8 0.08* 
Pathologic Parameters 
 
Size (cm) (n=41;33) 3.60 3.20 0.33 
 
Weight (g) (n=29;18) 33.3 30.1 0.81 
 
R Laterality (n=63;54) 20 (31.7%) 19 (35.2%) 0.84 
 
L Laterality (n=63;54) 22 (34.9%) 17 (31.5%) 1.00 
Extra-adrenal  (n=63;54)   
       
Abdominal (n=9;15) 
                    
       Zuckerkandl (n=7;11) 
 
       Chest (n=9;15) 
 
       Neck (n=9;15) 
9 (14.3%) 15 (27.8%) 0.11 
7 (77.8%) 11 (73.3%) 1.00 
2 (28.6%) 7 (64.0%) 0.33 
0 3 (20.0%) 0.27 
1 (11.1%) 0 0.37 
 
Synchronous (Multifocality) 
(n=65;55) 26 (40.0%) 33 (60%) 0.04* 
Pheo, pheochromocytoma; Dx, diagnosis; y, years 
p < 0.05 = significant 
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The category of most interest was the age at first diagnosis of pheochromocytoma.  We 
observed (Table 7) that pheochromocytoma was diagnosed at a significantly younger mean age 
in Family 2 (mean 19.7 y, range 8-47 y, p =0.02), compared to a mean age of 28.8 y in Family 1 
(range 6-72 y).  Additionally, Family 2 pheochromocytomas were more likely to be multifocal (p 
=0.04), since 60% of Family 2 tumors were synchronous compared to 40% of tumors in Family 
1.  Furthermore, a larger proportion of pheochromocytoma in Family 2 was extra-adrenal, with 
27.8% classified as paraganglioma, compared to 14.3% in Family 1, although the difference did 
not reach significance.   
The most common location of paraganglioma in both families was the abdomen (77.8% 
and 73.3% in Family 1 and 2, respectively).  Although Family 2 abdominal paragangliomas were 
much more often at the Organ of Zuckerkandl (located at the bifurcation of the aorta) (64.0% vs. 
28.6%) again the numbers were small and the difference did not reach significance.  Chest 
paragangliomas were more common in Family 2 (20.0% vs. 0).  There was one neck 
paraganglioma in Family 1 (11.1%) and none in Family 2. Although not statistically significant, 
pheochromocytoma in Family 1 also appeared to be more likely to be diagnosed by symptoms 
rather than routine screening.  Pheochromocytomas in Family 1 were also more likely secrete 
norepinephrine only preoperatively, which was the case for 70.4% of pheochromocytoma in 
Family 1, compared to 48.5% of pheochromocytoma in Family 2.  Size, weight and laterality (R 
vs. L adrenal gland) were shown to be the same between the 2 families.   
We defined metachronous pheochromocytoma to be a new tumor arising at a site 
different from that of a previously resected pheochromocytoma.  Local recurrence at the site of 
prior resection, and distant metastasis, were also tracked.  Metachronous pheochromocytoma was 
frequent in both families (33.2% and 20% in Family 1 and 2, respectively), occurring  at a mean 
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of 7.8 y (range 1-25 y) after the first diagnosis in Family 1 compared to a mean of 12.8 y, (range 
1-31 y) in Family 2 (p=0.08).  Pheochromocytoma in Family 1 was shown to be significantly 
more morbid across almost all measures, except recurrence (Table 8).  Accordingly, 100% of 
informative pheochromocytoma in Family 2 was biochemically cured post-operatively, whereas 
only 76% of pheochromocytoma in Family 1 was shown to be biochemically cured (p < 0.05).  
Additionally, 20% of tumors in Family 1 were metastatic (p < 0.05), compared to 4.8% of 
tumors in Family 2.  Note that multiple metastases at the time of death i.e. autopsy findings were 
not counted individually, and that malignant pheochromocytoma is not determined by histology, 
only long-term follow-up.  Rates of pheochromocytoma classified as recurrent were the same 
between the 2 families.  The details of the 5 individuals diagnosed with pheochromocytoma in 
Family 1 who died from complications of the tumor (dead of disease [DOD]) are given in Table 
9.  In Family 2, there is no evidence that anyone has died yet due to complications of 
pheochromocytoma.  However, one member did die of brain hemangioblastoma, another 
complication of VHL type 2A often leading to morbidity and mortality (Table 7).   
 
Table 8.  Measures of Morbidity and Mortality of Pheochromocytoma 
 Family 1 Family 2 p value  
Biochemical cure      
(n=50;49) 38 (76.0%) 49 (100%) 0.0002* 
Recurrence        
(n=63;62) 1 (1.6%) 3 (4.8%) 0.36 
Metastasis        
(n=64;62) 13 (20.0%) 3 (4.8%) 0.01* 
DOD                          
(n=30;33) 5 (16.7%) 0 0.02* 
DOD, dead of disease 
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Table 9.  Individuals Dead of Disease (DOD)  
 Individual Age of Death Cause Details 
Family 1 
V-16 35 Metastatic pheo, MI 
Organ of Zuckerkandl pheo, 6 
Metastatic pheo (liver), 11 
Metastatic pheo (liver, bowel, 
lung, periaortic LN), 35 
IV-4 56 Infarction of cerebellum Cerebellar HB, R periadrenal pheo dx at autopsy 
IV-6 48 MI L pheo, 37 R pheo, 48 
IV-11 36 Metastatic pheo, MI 
L pheo, 21 
R pheo, 27 
L pheo, 27 
Metastatic pheo, 34 
IV-13 24 Hrt and renal failure; pheo dx by autopsy 
Retrospective dx by 
radiographic adrenal mass and 
clinical course 
Family 2 IV-10 38 Brain HB Brain HB, 18+35 
Pheo, pheochromocytoma; MI, myocardial infarction (heart attack); HB, hemangioblastoma 
 
3.4 SUMMARY OF PHENOTYPIC FINDINGS 
 
In conclusion, we observed autosomal dominant transmission of VHL type 2A in both of the 
studied kindreds.  We documented that pheochromocytoma was the most common tumor type in 
both families, with a penetrance of 71.4% and 66.1% in Family 1 and 2 respectively.  Penetrance 
was estimated using both clinically affected individuals and carriers of a VHL mutation and was 
the same between the families.  Furthermore, we observed phenotypic differences based on 
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genotype.  Malignant pheochromocytoma occurred in Family 1 in 20% of patients and in Family 
2 in only 4.8% of patients.  Pheochromocytoma in Family 1 (Y112H) was significantly more 
likely to be lethal, to present at a later age, and to be unifocal, whereas pheochromocytoma in 
Family 2 (Y98H) was significantly more likely to present at a younger age, to be multifocal, and 
to benign in behavior.  In addition, although not statistically significant, we observed trends in 
Family 1 towards earlier metachronous pheochromocytoma, diagnosis by symptoms rather than 
routine screening, and more secretion of norepinephrine alone, while Family 2 
pheochromocytoma was more likely to be extra-adrenal, and to be biochemically cured with 
resection.  
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4.0    DISCUSSION 
This study is unique in its clinical and phenotypic characterization of two very large 
multigenerational VHL type 2A kindreds.  Both have been described previously in the literature, 
but one family (Family 2) has never been described as a whole in detail, and characterization of 
the other family (Family 1) has not been updated for over 12 years.  With 24 members affected 
with pheochromocytoma at the time of last report in 1997, Family 1 is currently the largest 
kindred with pheochromocytoma described in the literature [Mulvihill et al. 1997], yet my thesis 
work considerably expands the family by adding 20 new cases of VHL, including 6 new 
diagnoses of pheochromocytoma.  Furthermore, this work describes for the first time the 
phenotypic expression of an even larger kindred with inherited pheochromocytoma (Family 2) in 
which we have diagnosed at least 37 members to date with pheochromocytoma.  This is the also 
first study of its kind to examine the expression patterns of pheochromocytoma, the most 
common manifestation of VHL type 2A, between 2 families with the 2 most frequent VHL type 
2A mutations, Y112H and Y98H (Family 1 and Family 2, respectively).   
4.1 VHL TYPE 2A EXPRESSION AMONG KINDRED MEMBERS 
Family 1 consists of at least 49 members with confirmed VHL type 2A, of whom 35 are 
clinically affected and 14 are asymptomatic.  Family 2 has at least 65 members with confirmed 
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VHL type 2A, of whom 47 are clinically affected and 18 remain asymptomatic.  All of the most 
common manifestations of VHL type 2A (pheochromocytoma, hemangioblastoma, retinal 
angioma, and RCC) are represented in each family, with pheochromocytoma being the most 
common manifestation in both families, and RCC being the least common tumor type. This 
phenotypic profile is consistent with the definition of VHL type 2A. Following 
pheochromocytoma, retinal angioma was the most frequent manifestation in Family 1, whereas 
hemangioblastoma was the most frequent manifestation in Family 2.  It is interesting that there 
were 3 total cases of RCC diagnosed between the 2 families as this tumor type is such an 
uncommon feature of VHL type 2A.  Although it could not be determined incontrovertibly that 
one case of “sporadic” RCC in Family 1 was not part of VHL type 2A, if this case is counted, 
our observed rate of RCC among VHL carriers in Family 1 would be about 4% which is a 
marked difference from many studies of type 2A kindreds that did not find any members affected 
with RCC.  Indeed, no previous publications involving either kindred have mentioned any of the 
3 cases of RCC that we discovered and report here.   
We observed no significant differences in the expression patterns of VHL type 2A 
manifestations among the 2 families.  Pheochromocytoma was found to be highly penetrant 
among VHL carriers in both families (71.4% and 66.1% in Family 1 and 2, respectively), and 
was the most frequent manifestation in clinically affected kindred members (85.7% and 78.7% in 
Family 1 and 2, respectively). However, the mean age at which pheochromocytoma was 
diagnosed in Family 2 was significantly younger (19.7 y) than in Family 1 (28.8 y) (discussed 
further below), and had a higher probability of being diagnosed by age range up to 50 years.  All 
cases of pheochromocytoma in Family 2 were diagnosed by age 50, whereas in Family 1 there 
were 6 cases diagnosed after the age of 50.  This is an important phenotypic difference between 
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VHL Type 2A families.  It is one that should be used to better design screening algorithms 
(Section 4.4).  We show here that phenotype affects age at first biochemical evaluation, and even 
well-being and longevity.   
As far as non-pheochromocytoma manifestations of VHL type 2A, the rates of retinal 
angioma differed the most between the 2 families, with Family 1 being more likely to be 
diagnosed with retinal angioma alone and in combination with other manifestations.  In total, 
about 37% of Family 1 members had retinal angioma, compared to approximately 19% in 
Family 2 (p = 0.08).  Family 1 also consistently had a higher probability of being diagnosed with 
retinal angioma at each age range up to 60 years old.  Although this may be a real difference 
between the phenotype of VHL type 2A in these families, we argue that the differing retinal 
angioma rates may actually reflect differences in screening compliance and/or delivery of 
medical care between the families.  As mentioned previously, in general, Family 2 presents for 
medical care much less often than Family 1 and thus is less likely to have routine screening, 
especially for retinal angioma, a manifestation that unless symptomatic would be unlikely to be 
diagnosed if there are financial constraints.  Similarly the higher rate of hemangioblastoma in 
Family 2 could represent a true phenotypic difference between the families, or may be a 
coincidental finding as the rates did not near statistical significance.   
The observed lower rates of HA and RA as compared to pheochromocytoma in both 
families support the theory that the development of retinal angioma and hemangioblastoma are 
more dependent on a combination of genetic and environmental factors, whereas a gene mutation 
alone may be sufficient to cause pheochromocytoma.  In other words, by Knudsen’s well-known 
“two-hit hypothesis” for carcinogenesis, in individuals with a germline VHL mutation, the “first 
hit” is likely to be responsible for the failure of apoptosis in adrenal medulla precursor cells that 
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ultimately leads to pheochromocytoma; as such, loss of heterozygosity (LOH) has not yet been 
observed in this tumor type.  Whereas certain unknown environmental influences may cause a 
“second hit” to occur that inactivates the remaining functional copy of the VHL gene and could 
be responsible for the development of retinal angioma or hemangioblastoma; indeed, these tumor 
types have been shown to display LOH (loss of heterozygosity).  Therefore, we feel the 
differences in the rates of retinal angioma and hemangioblastoma between the 2 families most 
likely reflect discrepancies in compliance and follow-up, as well as exposure to different 
environmental factors.   
Although not described in the Results, there were some interesting observations in 
Family 1 among the 3 branches of the family known to be affected with VHL (II-3, II-4, II-5) 
(Figure 3).  Out of 35 total clinically affected individuals in Family 1, 21 were in branch II-5 and 
7 each were in branches II-3 and II-4.  In regard to pheochromocytoma, 81% of II-5 branch 
members had pheochromocytoma as their only manifestation of the disease, as opposed to 29% 
of II-4 branch members and 0% of II-3 branch members (p<0.05).  Conversely, 86% of II-3 
branch members had pheochromocytoma in addition to another type 2A manifestation, as 
compared to 19% and 14% in branches II-5 and II-4, respectively (p<0.05).  Another interesting 
finding relates to retinal angioma penetrance.  As many as 57% of branch II-4 members had 
retinal angioma as their only manifestation of the disease, compared to 14% in branch II-3 and 
0% in branch II-5. No one in any of the branches had hemangioblastoma as their only 
manifestation of the disease, and branch II-4 had no cases or hemangioblastoma at all.  Taken 
together, these data suggest that branch II-5 members were more likely to be affected with 
pheochromocytoma, while branch II-3 members often had pheochromocytoma along with 
another type 2A manifestation, and branch II-4 members often had retinal angioma as their only 
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manifestation.  Indeed, during conversations with members of branch II-4, they expressed that 
they had inherited the “eye part of the disease” and were seemingly unconcerned or unaware of 
their pheochromocytoma or hemangioblastoma risks as most relatives affected with these tumor 
types were more distantly related to them. Some of these phenotypic differences between the 
branches of Family 1 are certainty significant and are consistent with the variability often found 
in families with autosomal dominant conditions.  It is possible that the variations within Family 1 
may be explained by distinct environmental and genetic factors. 
4.2 PHEOCHROMOCYTOMA EXPRESSION AMONG KINDRED MEMBERS  
A total of 65 pheochromocytomas from each family were evaluated, representing 30 individuals 
from Family 1 and 33 individuals from Family 2 with pheochromocytoma.  Clinical and 
pathological documentation was available for approximately 77% of pheochromocytoma 
examined.  Significant findings in Family 1 included a shorter time to new occurrence of 
pheochromocytoma, a higher rate of metastasis, a lower probability of being biochemically cured 
postoperatively, and a higher proportion of individuals who died from complications of 
pheochromocytoma.  Significant findings in Family 2 included an earlier age at diagnosis of first 
pheochromocytoma, a higher rate of multifocal tumors, and a higher proportion of patients with 
paraganglioma (especially those located at the Organ of Zuckerkandl).   
The mean age of diagnosis of pheochromocytoma between the 2 families may be the 
most interesting finding of this study.  Pheochromocytoma in Family 2 was diagnosed at a mean 
age of 19.7 years (range 8-47 y), compared to a mean age of 28.8 (range 6-72 y) in Family 1 
(p<0.05).  The average age of pheochrmocytoma diagnosis in Family 1 is consistent with reports 
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in the literature suggesting that in overall VHL disease pheochromocytoma presents at an 
average age of 30 years.  However, it is rather interesting that pheochromocytoma in Family 2 
presented almost 10 years earlier than the mean age of diagnosis, with the majority of cases 
(63.6%) being diagnosed before the age of 20 years.  Alternatively, in Family 1 only 36.6% of 
pheochromocytoma was diagnosed by the age of 20, though the majority (56.6%) was diagnosed 
by the age of 30.  If it is indeed true that having a germline VHL mutation is sufficient to cause 
pheochromocytoma, then the earlier age of diagnosis of pheochromocytoma in Family 2 could 
suggest that the specific mutation (Y98H) is less able to promote apoptosis of adrenal medulla 
precursor cells than the Y112H mutation. Of course, this finding of young age of 
pheochromocytoma diagnosis may be unique to Family 2 and not hold true for all individuals 
with Y98H mutations.   
Individuals in Family 2 were also more likely to be diagnosed with synchronous disease 
(50% vs. 27.7%) and a greater proportion of total pheochromocytoma in Family 2 was multifocal 
(60% vs. 40%) (p<0.05).  It has been reported that up to 58% of VHL pheochromocytoma is 
multifocal [Walther et al. 1999], so rather than it being unusual that Family 2 has a high rate of 
synchronous disease, the more interesting finding may be that Family 1 has a lower-than-
expected rate of synchronous pheochromocytoma.  Although not quite statistically significant 
(p=0.11), Family 2 was also found to have a higher rate of paraganglioma (27.8% vs. 14.3%).  
This higher rate of paraganglioma in Family 2 may help explain the higher rate of synchronous 
disease, and is in keeping with the findings of Clarke et al. [1998] that describe a higher risk for 
synchronous disease in patients with paraganglioma.  In VHL overall, about 12% of 
pheochromocytoma is predicted to be extra-adrenal and interestingly, paraganglioma has only 
been seen in families with missense mutations, most frequently those with Y98H mutations 
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[Walther et al., 1999].  Therefore, Family 2 had a rate of paraganglioma over 2 times higher than 
expected.  The majority of paraganglioma in both families was located in the abdomen (77.8% 
and 73.3%), with the Organ of Zuckerkandl being the most frequent location in Family 2 (64%).  
The more rare locations of paraganglioma are also worth mentioning; there were 3 cases of chest 
paraganglioma in Family 2, and 1 case of neck paraganglioma in Family 1.  Of the 15 cases of 
paraganglioma diagnosed in Family 2, 8 were the initial manifestation of VHL type 2A in that 
individual (53.3%).  In Family 1, of the 9 cases of paraganglioma, 4 were the initial 
manifestation of VHL type 2A in that individual (44.4%) (p<0.05).  This is a notable finding 
because at the present time, if a patient were to present with a paraganglioma, testing algorithms 
would invariably first lead to SDHB/SDHD gene testing rather than to VHL.  Granted, the 
individuals in this study have a family history of VHL, but as will be discussed later, they are not 
all fully aware of this diagnosis or its implications, therefore they may not be able to assert this 
during an evaluation.  Lastly, compared to pheochromocytoma which is malignant in about 5-
10% of cases, paraganglioma has been reported to be malignant 14-50% of the time, but despite 
Family 2 having a higher rate of paraganglioma, Family 1 had a higher rate of metastatic disease 
(discussed further below).    
The rate of metachronous pheochromocytoma was higher (32.3% vs. 20%) and occurred 
sooner in Family 1, at a mean of 7.8 years after first diagnosis, compared to 12.8 years in Family 
2 (p=0.08).  It is important to keep in mind that time to re-operation as a means to determine 
occurrence rate of metachronous disease is an inaccurate measure of the true rate, because we do 
not know exactly when the tumor occurred, only when surgery was performed.  This is a limiting 
factor for both families, however the data may be more accurate for Family 1 who generally had 
stricter biochemical follow-up.  Additionally, Family 1 pheochromocytoma was also 
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significantly more morbid than that of Family 2 across measures of metastasis, biochemical cure, 
and number of individuals dead of disease.  Approximately 5-10% of pheochromocytoma is 
malignant, with metastatic and recurrent disease being the best predictors of malignancy.  
Therefore, the 20% rate of metastatic disease observed in Family 1 (compared to 4.8% in Family 
2), is a very significant finding (p<0.05).  Interestingly, the rates of recurrent disease were higher 
in Family 2 (1.6% vs. 4.8% in Family 1 and 2, respectively), although sometimes it was difficult 
to determine recurrent disease based on operative reports, or in 1 case in Family 2 where no 
operative report was available.  Also, while all informative pheochromocytomas in Family 2 
were shown to be biochemically cured post-operatively, 24% of pheochromocytoma in Family 1 
continued to secrete high levels of catecholamines post-operatively (p<0.05), which could be 
suggestive of subclinical synchronous or metastatic disease.  Lastly, we know of 5 individuals in 
Family 1 who have died from complications of pheochromocytoma, usually as the direct result 
of a heart attack.  To the best of our knowledge, no one in Family 2 has died from 
pheochromocytoma, although some individuals had symptoms suggestive of pheochromocytoma 
at the time of their death.  Taken together, this data suggest that pheochromocytoma in Family 1 
is more morbid and lethal than pheochromocytoma in Family 2 which tended to be more indolent 
in nature.   
4.3 BIOCHEMICAL PHENOTYPE OF VHL TYPE 2A PHEOCHROMOCYTOMA  
The biochemical profile of pheochromocytoma associated with VHL disease has been 
extensively studied, usually in comparison to MEN2-associated pheochromocytoma to highlight 
their distinct biochemical and clinical phenotypes.  It is well established that VHL-associated 
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pheochromocytoma tends to secrete norepinephrine/normetanephrine, while MEN-2-associated 
pheochromocytoma is characterized by epinephrine/metanephrine secretion [Eisenhofer et al., 
2001; Walther et al., 1999].  This finding was confirmed by our study, as the majority of 
pheochromocytoma in both families (70.4% and 48.5%, respectively) was shown to secrete 
norepinephrine only.  The underlying mechanism of this specific secretion profile is related to 
the expression of 2 enzymes in the catecholamine metabolism pathway: tyrosine hydroxylase 
(TH) is the rate-limiting enzyme in catecholamine synthesis, and phenylethanolamineN-
methyltransferase (PNMT) is responsible for converting norepinephrine to epinephrine 
[Eisenhofer et al., 2001] (Figure 2).  Pheochromocytoma in MEN2 is characterized by an 
adrenergic biochemical phenotype as it expresses both PNMT and TH, whereas 
pheochromocytoma in VHL expresses negligible PNMT and greatly reduced amounts of TH, 
thus displaying a nonadrenergic biochemical profile [Eisenhofer et al., 2001].   
It is these differences in enzyme expression that contribute to the distinct clinical 
phenotype of pheochromocytoma in each disease; MEN2 patients have a higher frequency of 
hypertension (usually paroxysmal in nature) and symptoms than VHL patients due to higher 
rates of catecholamine synthesis and the fact that epinephrine has more potent vascular and 
metabolic effects than norepinephrine [Eisenhofer et al., 2001; Hjemdahl, Belfrage, Daleskog, 
1979].  In other studies, only 8-30% of patients with VHL had symptoms (“spells”), and about 
18% of patients had hypertension (usually sustained) [Eisenhofer et al., 2001; Walther et al., 
1999].  In our study, a large proportion of pheochromocytoma in both families was diagnosed by 
symptoms (which included spells and/or hypertension); 80.8% of pheochromocytoma in Family 
1 was diagnosed by symptoms, compared to 67.3% in Family 2 (p=0.17).  As several members 
in each family had multiple pheochromocytomas, some that presented with symptoms and others 
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that were diagnosed through screening, we were however unable to say how many individuals in 
general had signs and symptoms of pheochromocytoma.  Another notable finding from our study 
was that 2 adrenal pheochochromocytomas in Family 1 that were both diagnosed as a result of 
symptoms were found to be non-functional.  Although it is not uncommon for paragangliomas to 
be non-functional, this is a rare finding for pheochromocytoma that by definition is located in the 
adrenal gland.  Although symptoms were present in both individuals, their severity varied; one 
individual (IV-15) presented with hypertension, headaches, sweating, palpitations, 
nervousness/anxiety, and nocturia while the other individual (V-2) had hypertension alone.  We 
did not identify any individuals with non-functioning pheochromocytoma in Family 2.   
As MEN2 and VHL are caused by mutations in separate genes (RET and VHL, 
respectively), it is believed that the differences in clinical and biochemical expression of 
associated pheochromocytomas are due to the expression of different genes that control 
catecholamine synthesis [Eisenhofer et al., 2001].  It would be interesting to see if there were any 
differences in biochemical expression of VHL-associated pheochromocytoma based on mutation 
type.  Although most likely not attributable to mutation type, it is still a notable finding that the 
majority of the pheochromocytoma in our study was diagnosed by symptoms even though they 
secreted primarily norepinephrine.  
4.4 VHL TYPE 2A SCREENING RECOMMENDATIONS  
As mentioned in section 3.2.1, the rates of pheochromocytoma reported in the literature in 
Family 1 since 1962 have remained consistently high.  Certainly, we have come a long way since 
Dr. Tisherman’s initial investigation into the underlying cause of a familial aggregation of 
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pheochromocytoma.  Detection methods for pheochromocytoma have greatly improved and 
localization of the VHL gene has allowed for presymptomatic diagnosis in at-risk family 
members and confirmatory diagnosis in affected individuals.  Pheochromocytoma is a very 
frequently occurring tumor in VHL type 2A and a very serious complication of the disease, as 
death can result from severe hypertension or from metastatic spread.  It is crucial to screen 
carefully and consistently for pheochromocytoma, and it has become very clear that relying on 
infrequent measures of blood pressure as the sole means of screening is dangerous.  In Dr. 
Carty’s practice in endocrine surgery, patients with known VHL Type 2A (any route of 
diagnosis) or patients at risk who are unable to comply with recommended mutational analysis, 
are asked to undergo examination that includes yearly plasma metanephrine testing, radiologic 
imaging as indicated by prior or current disease, yearly retinal exam, and spine MRI every other 
year.    
4.5 PSYCHOSOCIAL ISSUES AMONG KINDREDS  
These families were very interesting to study for many reasons aside from their type 2A VHL 
manifestations.  What is initially striking about the families is their sheer size and fecundity.  The 
number of individuals in generation V of Family 2 is particularly staggering.  Typically with 
heritable genetic diseases, families are carefully planned, particularly with autosomal dominant 
conditions in which each child born is at 50% risk of being affected with the disorder.  Of course, 
in early generations little was known about VHL and its inheritance patterns.  Even though each 
individual I spoke with was unique, I did observe a general pattern of thinking and behavior 
between the 2 families.  Members of Family 1 were generally less knowledgeable about their 
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VHL disease and their family history, while members of Family 2 were more educated about 
VHL disease and their family history but at the same time were less likely to seek consistent 
medical care.  It is unclear whether the inconsistent follow-up observed in Family 2 is due to 
financial concerns, bravery or denial.  In both families, there was a clear persisting 
misconception that if you are not experiencing any symptoms, then you do not have 
pheochromocytoma.  Most family members live a distance from Pittsburgh, and were opposed to 
traveling for evaluation thus it may also be that their local doctors are not as knowledgeable 
about the management of VHL and pheochromocytoma.    
It was surprising that both families downplayed the seriousness of the disease, with denial 
being more outwardly evident in Family 1.  One particular case in Family 1 illustrates the 
implications in some members of this family: a 21 year-old man was first diagnosed with 
pheochromocytoma at the age of 8 and had yearly follow-up in his community by 24-hour urine 
testing until age 16.  At this point, he did not return for any further evaluation, although he 
continues to live with his father who has been dying from metastatic pheochromocytoma for 
several years.  At 21 this young man had testicular discomfort, on abdominal CT had another 
pheochromocytoma, and only then consulted one of the physicians in Dr. Carty’s group, but 
when his disease was discussed he replied, “and what is VHL?”.  He also did not realize that he 
could pass the disease on to his future children.  He was referred to Endocrine Genetics Clinic, 
where he had the opportunity to meet with a genetic counselor for education and to have his 
questions answered.  He elected to pursue genetic testing for the benefit of his future children 
and was found to carry the Y112H mutation, which was previously identified in other members 
of his family.  He also did not seem to comprehend how serious his father’s disease is, saying he 
was “doing fine” when he is clearly one of the worst cases in the family.  The patient is getting 
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married soon was somewhat overwhelmed and stressed by the information that was provided.  
Although certain members of Family 1 were well-informed about VHL, this case illustrates that 
there is limited information sharing among some members (of any kindred).   
Family 2 members seemed to be more concerned about the disease, yet did not seem to 
understand the importance of close follow-up.  Almost every member of Family 2 that I spoke 
with commented on the 14 siblings in generation V of whom 13 have pheochromocytoma.  Many 
wondered if the mother of these children also had VHL and if that might be why 13 of the 
children were affected.  Although not shown in the Family 2 pedigree, there were at least 3 
reported cases of consanguinity, though the known pairs were somewhat distantly related and as 
far as we know, only one parent was affected with VHL in each instance.  We have no evidence 
that the parents of the 14 siblings in generation V were close relatives, although it cannot be 
ruled out of course.    Consanguinity was also noted in Family 1, though most of the cases 
occurred in early generations.  
4.6 LIMITATIONS OF STUDY 
Careful consideration has gone into the acquisition and processing of this data, but there are still 
a number of limitations to this study.  First, although these families make up a large proportion 
of individuals identified to date with VHL type 2A, since the study only includes 2 families the 
findings cannot be generalized to all type 2A VHL, nor to all individuals with either the Y98H or 
Y112H mutation.  The families are very large, but the sample size is still relatively small.   
Although many steps were taken to ensure that all family members with VHL were 
identified, surely there are some members that we missed and possibly some members were 
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misidentified.  We were careful to verify data through a variety of sources if possible, but 
sometimes second-hand information was the only kind we were able to obtain and verification 
could not be obtained through clinical or pathological documentation.  There were multiple 
members in each family who were lost to follow-up and who could not be contacted to discuss 
the study, their personal history of VHL, or to obtain their medical records.  Also, I was unable 
to obtain some family members’ medical records when the surgery occurred so long ago that the 
records had since been destroyed.   
Many members of each family did not receive consistent follow-up, which could 
potentially lead to underestimation of rates of occurrence or re-occurrence of manifestations if a 
thorough evaluation did not take place.  Additionally, we identified about 18 individuals in 3 
smaller kindreds with VHL/pheochromocytoma who either had the Y98H mutation (Family 2) or 
were a part of Dr. Tisherman’s files but had not undergone genetic testing to the best of our 
knowledge.  We used many sources to attempt to link these members to one of the 2 studied 
kindreds, but were unable to do so. So although our phenotypic characterization of the families 
was as thorough as possible, it is by no means complete.   
 This is a study of genotype-phenotype correlations, and we did indeed find some 
significant differences between the 2 families in the expression of type 2A VHL disease, 
particularly related to the clinical and pathological phenotype of pheochromocytoma.  Both 
families are large and the majority of the members live in Western Pennsylvania.  However, as 
discussed previously there are certainly differences between the families with regard to 
compliance and delivery of medical care, and we can assume different lifestyles and exposures to 
environmental factors.  As we are unable to take these variables into account in our analysis, we 
cannot determine if the specific VHL gene mutations truly account for the observed phenotypic 
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differences between the 2 families.  Furthermore, we have insufficient knowledge regarding the 
mechanism of action of pheochromocytoma development with each mutation to hypothesize why 
we observed the differences in mean age at diagnosis, time to metachronous disease, and rate of 
synchronous and metastatic disease.   
4.7 FUTURE DIRECTIONS  
The establishment of our Inherited Endocrine Tumor Database allows for the continued tracking 
of these VHL type 2A families, as well as the opportunity to add newly identified VHL kindreds.  
It allows for the review of medical record information in order to perform retrospective research 
on VHL disease, as well as other inherited endocrine tumor syndromes, such as MEN1 and SDH 
where there are also large regional kindreds that are followed.   We hope that through the 
Inherited Endocrine Tumor Database we have the chance to continue follow Family 1 and 
Family 2 since they provide a unique opportunity to learn about the natural history of VHL type 
2A. 
Continued follow up could provide information about changes in patterns of behavior and 
screening over time in the 2 families.  In regard to Family 1 in particular, which has been 
described independently several times in the literature, our study serves as starting point to 
further update the characterization of this most interesting regional family.  We suspect that since 
Family 1 was first identified in 1962, a 50-year history of the family would be appropriate, 
paying particular attention to changing mortality rates and causes over time.  We would 
hypothesize that survival of individuals with VHL has improved over the 50 years that the family 
has been followed.  Other factors to assess, that would be expected to have improved over time, 
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would include age of death (adjusted for birth year), adverse events associated with a high risk of 
mortality (stroke/MI/cardiomyopathy/malignant pheochromocytoma etc), and operative 
mortality from pheochromocytoma (hard to fully attribute to genetics since operative 
improvements have occurred independently).  This future study would contribute greatly to the 
cancer genetics literature, helping to prove that knowing one’s genetic status does indeed make a 
difference in morbidity and mortality through presymptomatic genetic diagnosis and early 
surgical intervention.   
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5.0  CONCLUSION  
VHL type 2A is an autosomal dominant inherited endocrine tumor syndrome characterized by a 
high risk for pheochromocytoma, retinal angioma, and hemangioblastoma, and a low risk for 
renal cell carcinoma.  Our study of 2 large Western Pennsylvania VHL type 2A kindreds, each 
with a different mutation in exon 1 of the VHL gene (Y98H and Y112H), confirms this 
phenotypic expression profile.  
The 2 families displayed similar expression of VHL type 2A manifestations, including 
high penetrance and rates of pheochromocytoma and low penetrance of renal cell carcinoma.  
The rates of retinal angioma and hemangioblastoma differed most between the 2 families, but we 
hypothesize that these differences are more likely due to discrepancies in follow-up/compliance 
and exposure to environmental factors, rather than to mutational differences between the 
families.  Interestingly, there was a distinct difference in phenotypic expression of 
pheochromocytoma between the 2 families, as evidenced by measurement of a variety of clinical 
and pathological parameters.  It appears that pheochromocytoma in Family 1 (Y112H) is 
significantly more morbid and lethal than pheochromocytoma in Family 2 (Y98H) which seems 
manifest pheochromocytomas that are more indolent in nature.  However, pheochromocytoma in 
Family 2 was diagnosed on average a decade earlier than in Family 1 (19 vs. 29 years of age), 
which coincidentally is also a decade earlier than the average age of pheochromocytoma 
diagnosis in overall VHL.  There were multiple members in each family with metachronous 
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disease, but metachronous pheochromocytoma happened sooner after the first diagnosis in 
Family 1, although the difference of 5 years (8 vs. 13 years) between the families was not quite 
statistically significant.  Family 2 was more likely to have multifocal disease and to be diagnosed 
with extra-adrenal paraganglioma (both overall and as the first manifestation of the disease).   
These unique pheochromocytoma expression profiles may be attributable to the 
mutational differences of the families, particularly as germline mutations alone have been 
hypothesized to be responsible for the development of pheochromocytoma.  However, the 
molecular mechanism of action that causes pheochromocytoma has yet to be elucidated, but as 
alluded to before may involve protein kinase C signaling and microtubule stabilization.  As both 
the Y98H and Y112H mutations are missense mutations located in exon 1 of the VHL gene that 
replace tyrosine with histitine, it will be difficult to tease out differences between them that could 
result in unique phenotypic expression of pheochromocytoma.  Aside from the genotype-
phenotype information that can be gleaned from these families, they are an invaluable source of 
information regarding expression of VHL type 2A.  They are extremely fascinating human 
beings both clinically and psychosocially and it will be interesting to continue to follow them in 
the years to come.     
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APPENDIX A 
INSTITUTIONAL REVIEW BOARD APPROVAL LETTER 
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APPENDIX B 
DOCUMENTED PHEOCHROMOCYTOMA DATA 
Individual Pheo # 
Age 
at Dx Location, Laterality Paragang Synch. Recurr. Mets Dx Scrn vs. Sx 
Secretory pre-
op 
Size 
(cm) 
Weight 
(g) 
Biochem 
cure 
Time to 
Recurrence 
(y) F/U 
               
 Family 1               
III-6  1 54 L adrenal     Sx  7.5 146.0 ? 1  
III-6  2 55 R retroperitoneum Y    Sx  1.4  ?  
No f/u-
deceased 
III-10 1 51 L adrenal       7.0  ?  
No f/u-
deceased 
IV-4 1 56 R adrenal     
Autopsy 
finding  3.0  No  DOD 
IV-6 1 37 L adrenal     Sx  8.5  Implied 11  
IV-6 2 48 R adrenal       5.0  ?  
No f/u-
deceased 
IV-10 1 69 R adrenal     Sx Norepi 3.0 22.5 Y  
7y2mo- 
deceased 
IV-11 1 21 R adrenal  Y   Sx  3.0  Implied 6  
IV-11 1B 21 Preaortic (abd mets)  Y  Y Sx  8.0 88.0  6  
IV-11 2 27 L adrenal  Y   Scrn     7  
IV-11 2B 27 
Periadrenal (abd 
mets)  Y  Y Scrn     7  
IV-11 3 34 Distant mets    Y  Epi, norepi   No  DOD 
IV-12 1 72 R adrenal     Scrn Norepi 0.6 5.1 Y  4y5mo 
IV-13 1 24 L adrenal     Sx    No   DOD 
IV-15 1 21 R adrenal     Sx Nonfunctional 2.2 4.2 Implied 12  
IV-15 2 33 L adrenal     Scrn  6.0  Y  38y4mo 
V-2 1 40 R adrenal     Sx Nonfunctional 1.7    27y0mo 
V-3 1 38 L adrenal     Sx Norepi 2.8 27.1 Y  13y4mo 
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V-5 1 16 L adrenal     Sx  5.0  Implied 7  
V-5 2 23 
Retroperitoneal, abd 
LN    Y      25  
V-5 3 48 Glomus vagale Y          No f/u  
V-10 1 38 L adrenal     Sx  2.5  Y  26y0mo 
V-11 1 42 L adrenal     Sx Norepi 6.8 152.0 Implied 10  
V-11 2 52 L adrenal bed  Y Y Y Sx Normet, norepi 1.2  N 1  
V-11 2A 52 L adrenal LN  Y       N 1  
V-11 3 53 Thoracic LN    
Y-
regional Sx Met, normet   N 1  
V-11 4 54 Mediastinal LN    Y Sx Normet, norepi 5.0  N 1  
V-11 5 55 Retroperitoneal LN  Y  Y Scrn    N 2  
V-11 5B 55 L adrenal bed LN  Y  Y Scrn    N 2  
V-11 5C 55 R abd mass Y Y   Scrn    N 2  
V-11 6 57 Cervical region  Y  
Y-
distant Sx    N   
V-11 6B 57 
Lung + multiple mets 
(chest, abd, pelvis, 
lung)  Y  
Y- 
distant Sx    N  2y8mo 
V-13 1 31 Zuckerkandl Y    Scrn Normet 5.0 35.0 Y  3y8mo 
V-16 1 6 Zuckerkandl Y    Sx     5  
V-16 2 11 Liver    Y      25  
V-16 3 36 
Liver, bowel, lung, 
peri-aortic LN    Y 
Autopsy 
finding VMA, norepi     DOD 
V-17 1 25 R adrenal  Y   Sx  4.0  Y  31y11mo 
V-17 1B 25 L adrenal  Y   Sx    Y  31y11mo 
V-18 1 40 R adrenal     Sx Norepi 2.5 4.0 Y  1y9mo 
V-21 1 35 L adrenal  Y   Sx Norepi 4.0 19.4 Y  
3y0mo- 
deceased 
V-21 1B 35 R adrenal  Y   Sx Norepi 3.5 12.0 Y  
3y0mo- 
deceased 
V-21 1C 35 R Porta Cava Y Y   Sx ? 3.0 6.0 Y  
3y0mo- 
deceased 
VI-1 1 22 L adrenal     Scrn    Implied 8  
VI-1 2 30 R adrenal     Sx    Y  16y2mo 
VI-2 1 24 R adrenal  Y   Sx  7.0  Y  13y0mo 
VI-2 1B 24 R adrenal  Y   Sx  2.3  Y  13y0mo 
VI-2 1C 24 R adrenal  Y   Sx  1.5  Y  13y0mo 
VI-7 1 8 R adrenal     Sx Norepi 2.3 6.0 Y 13 13y1mo 
VI-7 2 21 L adrenal     Sx Norepi, normet 
4.8 
(per 
CT)  
awaiting 
rsxn   
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VI-10 1 13 L adrenal     Scrn Norepi 2.4  Y  17y3mo 
VI-11 1 10 L periaortic Y    Sx Norepi 1.6  Implied 4  
VI-11 2 14 R adrenal     Sx VMA 1.6  Y  18y4mo 
VI-13 1 10 R adrenal     Sx VMA 2.5  Implied 2  
VI-13 2 12 L adrenal      VMA   Y  20y3mo 
VI-14 1 12 R adrenal     Sx VMA 5.5 45 Implied 15  
VI-14 2 27 L adrenal     Sx Norepi 1.5 8 Y  9y4mo 
VI-16 1 9 R pararenal Y    Sx  4  Implied 3  
VI-16 2 12 R adrenal     Sx  3.2  Implied 4  
VI-16 3 16 L adrenal  Y   Sx Norepi 1.6  Y  4y4mo 
VI-16 3B 16 L adrenal  Y   Sx Norepi 0.7  Y  4y4mo 
VI-16 3C 16 L extra-adrenal Y Y   Sx Norepi 1.5  Y  4y4mo 
VII-1 1 17   Y          
VII-1 1B 17   Y          
VII-4 1 12 L adrenal     Scrn Norepi, normet 3.9 7.9 Y  3y1mo 
VII-5 1 11 R adrenal  Y   Sx Norepi, epi 2.0 6.0 Y  3y1mo 
VII-5 1B 11 L adrenal  Y   Sx Norepi, epi 2.5 5.0 Y  3y1mo 
               
 Family 2              
IV-1 1 47      Scrn    Y  21y0mo 
IV-2 1 29 L adrenal       2.5 6.75 ?  No f/u 
IV-5 1 30            31y0mo 
IV-6 1 28 R adrenal      Sx    Implied   
IV-6 2 40 R Paravertebral Y  Y  Scrn    ?  19y0mo 
IV-10 1 41 L adrenal     Sx      
23y0mo- 
deceased 
IV-13 1 37 R adrenal     Sx    Implied 31  
IV-13 2 68 R adrenal bed  Y Y  Sx Norepi, VMA 5.0 89.5 Y  2mo 
IV-13 3 68 L adrenal  Y   Sx Norepi, VMA 1.2 40.0 Y  2mo 
IV-13 4 68 Thoracic Y Y   Sx Normet   
Awaiting 
rsxn   
V-1 1 9      Sx    Implied 3  
V-1 2 12          Implied 6  
V-1 3 18            No f/u 
V-2 1 28          ?   
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V-4 1 11 R adrenal     Sx Norepi 3.0 200.0 Implied 17  
V-4 2 29 L adrenal     Sx Norepi 3.0 13.3 Y  10y0mo 
V-9 1 16          Implied 11  
V-9 2 27            11y0mo 
V-14 1 15 L adrenal  Y   Scrn 
VMA, norepi, 
epi 2.8  Implied 12  
V-14 1B 15 R adrenal  Y   Scrn 
VMA, norepi, 
epi 3.0  Implied 12  
V-14 2 27 
R paravertebral 
thoracic Y    Sx Norepi, met 4.0 35.0 no f/u tests  20y0mo 
V-18 1 14 R adrenal  Y   Sx 
Norepi, met?, 
VMA? 4.0 20 Y  32y0mo 
V-18 1B 14 L adrenal  Y   Sx 
Norepi, met?, 
VMA? 5.0 18 Y  32y0mo 
V-18 1C 14 L adrenal LN  Y  
Y-
regional Sx 
Norepi, met?, 
VMA? 1.5  Y  32y0mo 
V-19 1 11 L adrenal         Implied 22  
V-19 2 33 R adrenal     Scrn VMA, norepi 2.8 30.0 Y 4 11y0mo 
V-19  2B 33 L thoracic    Y Scrn  6.5 60.0 Y 4 11y0mo 
V-19 3 37 L lung metastasis    Y Scrn    Y  11y0mo 
V-20 1 9 L adrenal  Y   Sx VMA, norepi 1.0 0.8 Y  34y0mo 
V-20  1B 9 Zuckerkandl Y Y   Sx VMA, norepi 1.3 1.3 Y  34y0mo 
V-20  1C 9 R adrenal  Y   Sx VMA, norepi 7.0 57.0 Y  34y0mo 
V-21 1 8 R adrenal         Implied 21  
V-21 2 29 R adrenal bed  Y Y    6.2 49.0 Y   
V-21  2B 29 L adrenal  Y     4.0 42.0 Y  10y9mo 
V-22 1 10      Scrn    Y  29y0mo 
V-23 1 14 R adrenal         Implied 13  
V-23 2 27 L adrenal     Scrn 
Normet, met, 
VMA 3.3 8.2 Y  8y5mo 
V-25 1 23 R adrenal     Sx Norepi 4.5 10.1 Y  10y2mo 
V-26 1 8 R adrenal  Y   Sx Norepi, VMA 5.6 25.0 Implied 13  
V-26 1B 8 Zuckerkandl Y Y   Sx ? 2.0 4.4 Implied 13  
V-26 2 21 L adrenal     Scrn Norepi 2.4 16.8 Y  10y4mo 
V-29 1 14 R periaortic Y Y   Scrn Norepi 3.0 8.0 ? 1  
V-29 1B 14 L adrenal  Y   Scrn Norepi 4.0 42.0 ? 1  
V-29 2 15 R adrenal  Y   Sx Norepi 1.5  Y  9y6mo 
V-29 2B 15 
R inferior renal 
hilum Y Y   Sx Norepi 3.2  Y  9y6mo 
V-30 1 12 L adrenal      Sx      2y0mo 
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V-31 1 16 Thoracic Y Y   Scrn Norepi 3.0  Y  2y2mo 
V-31  1B 17 Zuckerkandl Y Y   Scrn ? 1.5 2.4 Y  2y2mo 
V-35 1 41 R adrenal  Y   Sx Norepi, VMA 1.8 12.0 Y  3y0mo 
V-35  1B 41 L adrenal  Y   Sx Norepi, VMA 1.5 3.0 Y  3y0mo 
V-36 1 31 L adrenal     Sx Norepi, VMA 2.3 18.47 Y  6mo 
V-37 1 24 R adrenal     Sx Norepi 3.0 12.8 Y  4y0mo 
V-40 1 36 Zuckerkandl Y    Sx Norepi 4.0  Y  1mo 
VI-4 1 15          ?  12y0mo 
VI-6 1 18 R adrenal     Sx Norepi 3.1  Y  2y9mo 
VI-7 1 11 R adrenal   Y   Sx  5.5  Y  9y0mo 
VI-7 1B 11 Zuckerkandl Y Y   Sx  3.5 10.0 Y  9y0mo 
VI-7 1C 11 Zuckerkandl Y Y   Sx  1.4  Y  9y0mo 
VI-7 1D 11 Zuckerkandl Y Y   Sx  0.9  Y  9y0mo 
VI-9 1 10 R adrenal  Y       ?   
VI-9 1B 10 L adrenal  Y       ?  No f/u 
VI-10 1 11   Y       ?   
VI-10 1B 11 Periaortic Y Y       ?  No f/u 
VI-12 1 14 L adrenal  Y   Scrn Norepi 4.2 37.5 Y  1y3mo 
VI-12  1B 14 L adrenal  Y   Scrn Norepi 1.8  Y  1y3mo 
VI-16 1 9 
Mid retroperitoneum 
(aortocaval space) Y    Sx Norepi 2.6  Y  5mo 
Pheo, pheochromocytoma; Paragang, paraganglioma; Synch, synchronous; Recurr, recurrence; Mets, metastasis; Dx, diagnosis; Scrn, screening;  
Sx, symptoms; F/U, follow-up; LN, lymph nodes; Norepi, norepinephrine; Epi, epinephrine; Met, metanephrine  
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